ID APC_HUMAN Reviewed; 2843 AA. AC P25054; B7Z2B6; D3DT03; Q15162; Q15163; Q93042; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 16-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 276. DE RecName: Full=Adenomatous polyposis coli protein; DE Short=Protein APC; DE AltName: Full=Deleted in polyposis 2.5; GN Name=APC {ECO:0000312|HGNC:HGNC:583}; Synonyms=DP2.5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A AND 2), AND VARIANT ASP-1822. RC TISSUE=Fetal brain; RX PubMed=1678319; DOI=10.1016/0092-8674(81)90022-2; RA Joslyn G., Carlson M., Thliveris A., Albertsen H., Gelbert L., Samowitz W., RA Groden J., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., RA Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J.D., RA Wasmuth J.J., le Paslier D., Abderrahim H., Cohen D., Leppert M., White R.; RT "Identification of deletion mutations and three new genes at the familial RT polyposis locus."; RL Cell 66:601-613(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND VARIANT ASP-1822. RX PubMed=1651562; DOI=10.1126/science.1651562; RA Kinzler K.W., Nilbert M.C., Su L.-K., Vogelstein B., Bryan T.M., Levy D.B., RA Smith K.J., Preisinger A.C., Hedge P., McKechnie D., Finniear R., RA Markham A., Groffen J., Boguski M.S., Altschul S.F., Horii A.K., Ando H., RA Miyoshi Y., Miki Y., Nishisho I., Nakamura Y.; RT "Identification of FAP locus genes from chromosome 5q21."; RL Science 253:661-665(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH ARHGEF4, AND IDENTIFICATION IN A COMPLEX WITH ARHGEF4 AND RP CTNNB1. RX PubMed=10947987; DOI=10.1126/science.289.5482.1194; RA Kawasaki Y., Senda T., Ishidate T., Koyama R., Morishita T., Iwayama Y., RA Higuchi O., Akiyama T.; RT "Asef, a link between the tumor suppressor APC and G-protein signaling."; RL Science 289:1194-1197(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-1822. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1135 (ISOFORM 1B). RC TISSUE=Amygdala {ECO:0000312|EMBL:BAH11802.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1506-1524. RX PubMed=1310068; RA Miki Y., Nishisho I., Horii A., Miyoshi Y., Utsunomiya J., Kinzler K.W., RA Vogelstein B., Nakamura Y.; RT "Disruption of the APC gene by a retrotransposal insertion of L1 sequence RT in a colon cancer."; RL Cancer Res. 52:643-645(1992). RN [8] RP INTERACTION WITH ALPHA- AND BETA-CATENINS. RX PubMed=8259519; DOI=10.1126/science.8259519; RA Su L.-K., Vogelstein B., Kinzler K.W.; RT "Association of the APC tumor suppressor protein with catenins."; RL Science 262:1734-1737(1993). RN [9] RP INTERACTION WITH DLG1. RX PubMed=8638125; DOI=10.1126/science.272.5264.1020; RA Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G.-H., RA Kawahara T., Kobayashi S., Okada M., Toyoshima K., Akiyama T.; RT "Binding of APC to the human homolog of the Drosophila discs large tumor RT suppressor protein."; RL Science 272:1020-1023(1996). RN [10] RP INTERACTION WITH DLG3. RC TISSUE=Fetal brain; RX PubMed=9188857; DOI=10.1038/sj.onc.1201087; RA Makino K., Kuwahara H., Masuko N., Nishiyama Y., Morisaki T., Sasaki J., RA Nakao M., Kuwano A., Nakata M., Ushio Y., Saya H.; RT "Cloning and characterization of NE-dlg: a novel human homolog of the RT Drosophila discs large (dlg) tumor suppressor protein interacts with the RT APC protein."; RL Oncogene 14:2425-2433(1997). RN [11] RP INTERACTION WITH APC2. RX PubMed=11691822; RA Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., RA King C.R., Byers S.W.; RT "Human APC2 localization and allelic imbalance."; RL Cancer Res. 61:7978-7984(2001). RN [12] RP INTERACTION WITH MAPRE1; MAPRE2 AND MAPRE3. RX PubMed=14514668; DOI=10.1074/jbc.m306194200; RA Bu W., Su L.-K.; RT "Characterization of functional domains of human EB1 family proteins."; RL J. Biol. Chem. 278:49721-49731(2003). RN [13] RP UBIQUITINATION. RX PubMed=15355978; DOI=10.1074/jbc.m404655200; RA Choi J., Park S.Y., Costantini F., Jho E.-H., Joo C.-K.; RT "Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome RT pathway in a process facilitated by Axin."; RL J. Biol. Chem. 279:49188-49198(2004). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP SUBCELLULAR LOCATION, INTERACTION WITH SCRIB, AND MUTAGENESIS OF THR-2841 RP AND VAL-2843. RX PubMed=16611247; DOI=10.1111/j.1365-2443.2006.00954.x; RA Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T., RA Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y.; RT "Human scribble, a novel tumor suppressor identified as a target of high- RT risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous RT polyposis coli."; RL Genes Cells 11:453-464(2006). RN [16] RP FUNCTION, INTERACTION WITH MAPRE1 AND ACTIN, AND PHOSPHORYLATION. RX PubMed=17293347; DOI=10.1074/jbc.m610615200; RA Moseley J.B., Bartolini F., Okada K., Wen Y., Gundersen G.G., Goode B.L.; RT "Regulated binding of adenomatous polyposis coli protein to actin."; RL J. Biol. Chem. 282:12661-12668(2007). RN [17] RP FUNCTION, AND INTERACTION WITH SPATA13. RX PubMed=17599059; DOI=10.1038/sj.onc.1210574; RA Kawasaki Y., Sagara M., Shibata Y., Shirouzu M., Yokoyama S., Akiyama T.; RT "Identification and characterization of Asef2, a guanine-nucleotide RT exchange factor specific for Rac1 and Cdc42."; RL Oncogene 26:7620-7627(2007). RN [18] RP DEUBIQUITINATION. RX PubMed=18281465; DOI=10.1101/gad.463208; RA Tran H., Hamada F., Schwarz-Romond T., Bienz M.; RT "Trabid, a new positive regulator of Wnt-induced transcription with RT preference for binding and cleaving K63-linked ubiquitin chains."; RL Genes Dev. 22:528-542(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2671, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780; SER-1042; SER-1360; RP SER-1861; SER-1863; SER-1864; THR-2151; SER-2260; SER-2270; SER-2283; RP SER-2473; SER-2535; SER-2671; SER-2674; THR-2679 AND SER-2789, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY. RX PubMed=19527921; DOI=10.1016/j.canlet.2009.05.016; RA Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T.; RT "Adenomatous polyposis coli 1A is likely to be methylated as a passenger in RT human gastric carcinogenesis."; RL Cancer Lett. 285:182-189(2009). RN [23] RP INTERACTION WITH MAPRE1, AND SUBCELLULAR LOCATION. RX PubMed=19632184; DOI=10.1016/j.cell.2009.04.065; RA Honnappa S., Gouveia S.M., Weisbrich A., Damberger F.F., Bhavesh N.S., RA Jawhari H., Grigoriev I., van Rijssel F.J., Buey R.M., Lawera A., RA Jelesarov I., Winkler F.K., Wuthrich K., Akhmanova A., Steinmetz M.O.; RT "An EB1-binding motif acts as a microtubule tip localization signal."; RL Cell 138:366-376(2009). RN [24] RP FUNCTION. RX PubMed=19893577; DOI=10.1038/embor.2009.233; RA Kawasaki Y., Tsuji S., Muroya K., Furukawa S., Shibata Y., Okuno M., RA Ohwada S., Akiyama T.; RT "The adenomatous polyposis coli-associated exchange factors Asef and Asef2 RT are required for adenoma formation in Apc(Min/+)mice."; RL EMBO Rep. 10:1355-1362(2009). RN [25] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19151759; DOI=10.1038/onc.2008.478; RA Sagara M., Kawasaki Y., Iemura S.I., Natsume T., Takai Y., Akiyama T.; RT "Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization RT and are involved in HGF-induced cell migration."; RL Oncogene 28:1357-1365(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744 AND SER-780, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP INTERACTION WITH AMER1. RX PubMed=21498506; DOI=10.1074/jbc.m111.224881; RA Tanneberger K., Pfister A.S., Kriz V., Bryja V., Schambony A., Behrens J.; RT "Structural and functional characterization of the Wnt inhibitor APC RT membrane recruitment 1 (Amer1)."; RL J. Biol. Chem. 286:19204-19214(2011). RN [30] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=21643010; DOI=10.1038/onc.2011.201; RA Rohlin A., Engwall Y., Fritzell K., Goeransson K., Bergsten A., RA Einbeigi Z., Nilbert M., Karlsson P., Bjoerk J., Nordling M.; RT "Inactivation of promoter 1B of APC causes partial gene silencing: evidence RT for a significant role of the promoter in regulation and causative of RT familial adenomatous polyposis."; RL Oncogene 30:4977-4989(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1861; SER-1863 AND SER-1864, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP INTERACTION WITH AMER2. RX PubMed=22128170; DOI=10.1074/jbc.m111.308650; RA Pfister A.S., Tanneberger K., Schambony A., Behrens J.; RT "Amer2 protein is a novel negative regulator of Wnt/beta-Catenin signaling RT involved in neuroectodermal patterning."; RL J. Biol. Chem. 287:1734-1741(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-748; SER-908; RP SER-1042; SER-1371; SER-1385; THR-1438; SER-1774; SER-1861; SER-2260; RP SER-2283; SER-2569; SER-2674; SER-2724 AND SER-2789, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH JPT1. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [37] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=27217144; DOI=10.1038/srep26011; RA Yamaguchi K., Nagayama S., Shimizu E., Komura M., Yamaguchi R., Shibuya T., RA Arai M., Hatakeyama S., Ikenoue T., Ueno M., Miyano S., Imoto S., RA Furukawa Y.; RT "Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B RT is responsible for familial adenomatous polyposis."; RL Sci. Rep. 6:26011-26011(2016). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 2-55. RX PubMed=10926498; DOI=10.1006/jmbi.2000.3895; RA Day C.L., Alber T.; RT "Crystal structure of the amino-terminal coiled-coil domain of the APC RT tumor suppressor."; RL J. Mol. Biol. 301:147-156(2000). RN [39] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1021-1035 IN COMPLEX WITH CTNNB1. RX PubMed=11707392; DOI=10.1093/emboj/20.22.6203; RA Eklof Spink K., Fridman S.G., Weis W.I.; RT "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis RT coli revealed by the structure of an APC-beta-catenin complex."; RL EMBO J. 20:6203-6212(2001). RN [40] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2034-2049 IN COMPLEX WITH AXIN1, RP AND INTERACTION WITH AXIN1. RX PubMed=10811618; DOI=10.1093/emboj/19.10.2270; RA Spink K.E., Polakis P., Weis W.I.; RT "Structural basis of the axin-adenomatous polyposis coli interaction."; RL EMBO J. 19:2270-2279(2000). RN [41] RP STRUCTURE BY NMR OF 1578-1596 IN COMPLEX WITH ASAP1, AND INTERACTION WITH RP ASAP1. RX PubMed=20509626; DOI=10.1021/bi100563z; RA Kaieda S., Matsui C., Mimori-Kiyosue Y., Ikegami T.; RT "Structural basis of the recognition of the SAMP motif of adenomatous RT polyposis coli by the Src-homology 3 domain."; RL Biochemistry 49:5143-5153(2010). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 407-775, AND DOMAIN ARM REPEATS. RX PubMed=21871439; DOI=10.1016/j.bbrc.2011.08.044; RA Zhang Z., Lin K., Gao L., Chen L., Shi X., Wu G.; RT "Crystal structure of the armadillo repeat domain of adenomatous polyposis RT coli which reveals its inherent flexibility."; RL Biochem. Biophys. Res. Commun. 412:732-736(2011). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 396-732 IN COMPLEX WITH KHDRBS1, RP INTERACTION WITH KHDRBS1, AND MUTAGENESIS OF LYS-516 AND ARG-549. RX PubMed=22000517; DOI=10.1016/j.str.2011.07.013; RA Morishita E.C., Murayama K., Kato-Murayama M., Ishizuka-Katsura Y., RA Tomabechi Y., Hayashi T., Terada T., Handa N., Shirouzu M., Akiyama T., RA Yokoyama S.; RT "Crystal structures of the armadillo repeat domain of adenomatous polyposis RT coli and its complex with the tyrosine-rich domain of Sam68."; RL Structure 19:1496-1508(2011). RN [44] RP VARIANTS FAP1. RX PubMed=1651563; DOI=10.1126/science.1651563; RA Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., RA Koyama K., Utsunomiya J., Baba S., Hedge P., Markham A., Krush A.J., RA Petersen G.M., Hamilton S.R., Nilbert M.C., Levy D.B., Bryan T.M., RA Preisinger A.C., Smith K.J., Su L.-K., Kinzler K.W., Vogelstein B.; RT "Mutations of chromosome 5q21 genes in FAP and colorectal cancer RT patients."; RL Science 253:665-669(1991). RN [45] RP VARIANT FAP1 GLY-911. RX PubMed=1338904; DOI=10.1093/hmg/1.4.229; RA Miyoshi Y., Nagase H., Ando H., Ichii S., Nakatsuru S., Aoki T., Miki Y., RA Mori T., Nakamura Y.; RT "Somatic mutations of the APC gene in colorectal tumors: mutation cluster RT region in the APC gene."; RL Hum. Mol. Genet. 1:229-233(1992). RN [46] RP VARIANTS FAP1. RX PubMed=1338691; DOI=10.1093/hmg/1.8.559; RA Nakatsuru S., Yanagisawa A., Ichii S., Tahara E., Kato Y., Nakamura Y., RA Horii A.; RT "Somatic mutation of the APC gene in gastric cancer: frequent mutations in RT very well differentiated adenocarcinoma and signet-ring cell carcinoma."; RL Hum. Mol. Genet. 1:559-563(1992). RN [47] RP VARIANTS FAP1 MET-1292 AND TRP-1348, AND VARIANTS ASP-1118; VAL-1304 AND RP SER-2502. RX PubMed=1338764; DOI=10.1002/humu.1380010603; RA Nagase H., Miyoshi Y., Horii A., Aoki T., Petersen G.M., Vogelstein B., RA Maher E., Ogawa M., Maruyama M., Utsunomiya J., Baba S., Nakamura Y.; RT "Screening for germ-line mutations in familial adenomatous polyposis RT patients: 61 new patients and a summary of 150 unrelated patients."; RL Hum. Mutat. 1:467-473(1992). RN [48] RP VARIANTS FAP1 CYS-2621 AND PHE-2839. RX PubMed=1316610; DOI=10.1073/pnas.89.10.4452; RA Miyoshi Y., Ando H., Nagase H., Nishisho I., Horii A., Miki Y., Mori T., RA Utsunomiya J., Baba S., Petersen G.; RT "Germ-line mutations of the APC gene in 53 familial adenomatous polyposis RT patients."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4452-4456(1992). RN [49] RP VARIANTS FAP1 CYS-414; THR-784 AND LEU-1176. RX PubMed=8111410; DOI=10.1002/humu.1380020602; RA Nagase H., Nakamura Y.; RT "Mutations of the APC (adenomatous polyposis coli) gene."; RL Hum. Mutat. 2:425-434(1993). RN [50] RP VARIANT FAP1 TRP-99. RC TISSUE=Peripheral blood lymphocyte; RX PubMed=7833149; DOI=10.1016/0959-8049(94)00294-f; RA Dobbie Z., Spycher M., Huerliman R., Ammann R., Ammann T., Roth J., RA Mueller A., Mueller H., Scott R.J.; RT "Mutational analysis of the first 14 exons of the adenomatous polyposis RT coli (APC) gene."; RL Eur. J. Cancer 30A:1709-1713(1994). RN [51] RP VARIANT FAP1 GLY-722. RX PubMed=7833931; DOI=10.1093/hmg/3.9.1687; RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RT "Four novel mutations of the APC (adenomatous polyposis coli) gene in FAP RT patients."; RL Hum. Mol. Genet. 3:1687-1688(1994). RN [52] RP ERRATUM OF PUBMED:7833931. RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RL Hum. Mol. Genet. 3:1918-1918(1994). RN [53] RP INVOLVEMENT IN FAP1. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [54] RP INVOLVEMENT IN DESMD. RX PubMed=8940264; RA Eccles D.M., van der Luijt R.B., Breukel C., Bullman H., Bunyan D., RA Fisher A., Barber J., du Boulay C., Primrose J., Burn J., Fodde R.; RT "Hereditary desmoid disease due to a frameshift mutation at codon 1924 of RT the APC gene."; RL Am. J. Hum. Genet. 59:1193-1201(1996). RN [55] RP VARIANT HEPATOBLASTOMA CYS-1395. RX PubMed=8764128; RA Oda H., Imai Y., Nakatsuru Y., Hata J., Ishikawa T.; RT "Somatic mutations of the APC gene in sporadic hepatoblastomas."; RL Cancer Res. 56:3320-3323(1996). RN [56] RP VARIANT FAP1 ILE-171. RX PubMed=8990002; RX DOI=10.1002/(sici)1098-1004(1997)9:1<7::aid-humu2>3.0.co;2-8; RA van der Luijt R.B., Meera Khan P., Vasen H.F.A., Tops C.M.J., RA van Leeuwen-Cornelisse I.S.J., Wijnen J.T., van der Klift H.M., Plug R.J., RA Griffioen G., Fodde R.; RT "Molecular analysis of the APC gene in 105 Dutch kindreds with familial RT adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and RT southern analysis."; RL Hum. Mutat. 9:7-16(1997). RN [57] RP VARIANTS COLORECTAL CARCINOMA THR-880; ILE-890 AND VAL-1508. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [58] RP VARIANT LYS-1307. RX PubMed=9731522; DOI=10.1038/1666; RA Redston M., Nathanson K.L., Yuan Z.Q., Neuhausen S.L., Satagopan J., RA Wong N., Yang D., Nafa D., Abrahamson J., Ozcelik H., Antin-Ozerkis D., RA Andrulis I., Daly M., Pinsky L., Schrag D., Gallinger S., Kaback M., RA King M.-C., Woodage T., Brody L.C., Godwin A., Warner E., Weber B., RA Foulkes W., Offit K.; RT "The APC I1307K allele and breast cancer risk."; RL Nat. Genet. 20:13-14(1998). RN [59] RP VARIANTS LYS-1307 AND GLN-1317. RC TISSUE=Peripheral blood; RX PubMed=9724771; DOI=10.1073/pnas.95.18.10722; RA Frayling I.M., Beck N.E., Ilyas M., Dove-Edwin I., Goodman P., Pack K., RA Bell J.A., Williams C.B., Hodgson S.V., Thomas H.J.W., Talbot I.C., RA Bodmer W.F., Tomlinson I.P.M.; RT "The APC variants I1307K and E1317Q are associated with colorectal tumors, RT but not always with a family history."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10722-10727(1998). RN [60] RP VARIANT LYS-1307. RX PubMed=9731533; DOI=10.1038/1722; RA Woodage T., King S.M., Wacholder S., Hartge P., Struewing J.P., McAdams M., RA Laken S.J., Tucker M.A., Brody L.C.; RT "The APC I1307K allele and cancer risk in a community-based study of RT Ashkenazi Jews."; RL Nat. Genet. 20:62-65(1998). RN [61] RP VARIANT LYS-1307. RX PubMed=9973276; DOI=10.1086/302262; RA Gryfe R., Di Nicola N., Lal G., Gallinger S., Redston M.; RT "Inherited colorectal polyposis and cancer risk of the APC I1307K RT polymorphism."; RL Am. J. Hum. Genet. 64:378-384(1999). RN [62] RP VARIANTS GLY-1057; CYS-1171; ASP-1822 AND THR-2738. RX PubMed=9950360; RA Wallis Y.L., Morton D.G., McKeown C.M., Macdonald F.; RT "Molecular analysis of the APC gene in 205 families: extended genotype- RT phenotype correlations in FAP and evidence for the role of APC amino acid RT changes in colorectal cancer predisposition."; RL J. Med. Genet. 36:14-20(1999). RN [63] RP VARIANT FAP1 PRO-1184. RX PubMed=10470088; DOI=10.1038/12511; RA Lamlum H., Ilyas M., Rowan A., Clark S., Johnson V., Bell J.A., RA Frayling I.M., Efstathiou J., Pack K., Payne S., Roylance R., Gorman P., RA Sheer D., Neale K., Phillips R., Talbot I.C., Bodmer W.F., RA Tomlinson I.P.M.; RT "The type of somatic mutation at APC in familial adenomatous polyposis is RT determined by the site of the germline mutation: a new facet to Knudson's RT 'two-hit' hypothesis."; RL Nat. Med. 5:1071-1075(1999). RN [64] RP VARIANTS MDB VAL-1296; ILE-1472 AND GLY-1495. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [65] RP INVOLVEMENT IN DESMD. RX PubMed=10782927; DOI=10.1034/j.1399-0004.2000.570306.x; RA Couture J., Mitri A., Lagace R., Smits R., Berk T., Bouchard H.-L., RA Fodde R., Alman B., Bapat B.; RT "A germline mutation at the extreme 3' end of the APC gene results in a RT severe desmoid phenotype and is associated with overexpression of beta- RT catenin in the desmoid tumor."; RL Clin. Genet. 57:205-212(2000). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] PHE-1254. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [67] RP INVOLVEMENT IN GAPPS. RX PubMed=27087319; DOI=10.1016/j.ajhg.2016.03.001; RA Li J., Woods S.L., Healey S., Beesley J., Chen X., Lee J.S., RA Sivakumaran H., Wayte N., Nones K., Waterfall J.J., Pearson J., Patch A.M., RA Senz J., Ferreira M.A., Kaurah P., Mackenzie R., Heravi-Moussavi A., RA Hansford S., Lannagan T.R.M., Spurdle A.B., Simpson P.T., da Silva L., RA Lakhani S.R., Clouston A.D., Bettington M., Grimpen F., Busuttil R.A., RA Di Costanzo N., Boussioutas A., Jeanjean M., Chong G., Fabre A., RA Olschwang S., Faulkner G.J., Bellos E., Coin L., Rioux K., Bathe O.F., RA Wen X., Martin H.C., Neklason D.W., Davis S.R., Walker R.L., Calzone K.A., RA Avital I., Heller T., Koh C., Pineda M., Rudloff U., Quezado M., RA Pichurin P.N., Hulick P.J., Weissman S.M., Newlin A., Rubinstein W.S., RA Sampson J.E., Hamman K., Goldgar D., Poplawski N., Phillips K., RA Schofield L., Armstrong J., Kiraly-Borri C., Suthers G.K., Huntsman D.G., RA Foulkes W.D., Carneiro F., Lindor N.M., Edwards S.L., French J.D., RA Waddell N., Meltzer P.S., Worthley D.L., Schrader K.A., Chenevix-Trench G.; RT "Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and RT Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis RT Variant."; RL Am. J. Hum. Genet. 98:830-842(2016). RN [68] RP INVOLVEMENT IN GAPPS. RX PubMed=27343414; DOI=10.1016/j.gie.2016.06.023; RA Repak R., Kohoutova D., Podhola M., Rejchrt S., Minarik M., Benesova L., RA Lesko M., Bures J.; RT "The first European family with gastric adenocarcinoma and proximal RT polyposis of the stomach: case report and review of the literature."; RL Gastrointest. Endosc. 84:718-725(2016). RN [69] RP INVOLVEMENT IN MDB. RX PubMed=29753700; DOI=10.1016/s1470-2045(18)30242-0; RA Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., RA Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., RA Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., RA Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., RA Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., RA Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., RA Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., RA MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., RA Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., RA Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., RA Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., RA Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., RA Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., RA Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., RA Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., RA Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.; RT "Spectrum and prevalence of genetic predisposition in medulloblastoma: a RT retrospective genetic study and prospective validation in a clinical trial RT cohort."; RL Lancet Oncol. 19:785-798(2018). RN [70] RP INVOLVEMENT IN GAPPS. RX PubMed=33242120; DOI=10.1007/s12328-020-01290-6; RA Kanemitsu K., Iwatsuki M., Yamashita K., Komohara Y., Morinaga T., RA Iwagami S., Eto K., Nagai Y., Kurashige J., Baba Y., Yoshida N., Baba H.; RT "Two Asian families with gastric adenocarcinoma and proximal polyposis of RT the stomach successfully treated via laparoscopic total gastrectomy."; RL Clin. J. Gastroenterol. 14:92-97(2021). CC -!- FUNCTION: Tumor suppressor. Promotes rapid degradation of CTNNB1 and CC participates in Wnt signaling as a negative regulator. APC activity is CC correlated with its phosphorylation state. Activates the GEF activity CC of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)- CC induced cell migration. Required for MMP9 up-regulation via the JNK CC signaling pathway in colorectal tumor cells. Associates with both CC microtubules and actin filaments, components of the cytoskeleton CC (PubMed:17293347). Plays a role in mediating the organization of F- CC actin into ordered bundles (PubMed:17293347). Functions downstream of CC Rho GTPases and DIAPH1 to selectively stabilize microtubules (By CC similarity). Acts as a mediator of ERBB2-dependent stabilization of CC microtubules at the cell cortex. It is required for the localization of CC MACF1 to the cell membrane and this localization of MACF1 is critical CC for its function in microtubule stabilization. CC {ECO:0000250|UniProtKB:Q61315, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19151759, ECO:0000269|PubMed:19893577, CC ECO:0000269|PubMed:20937854}. CC -!- SUBUNIT: Forms homooligomers (Probable). Found in a complex consisting CC of ARHGEF4, APC and CTNNB1 (PubMed:10947987). Found in a complex CC composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). The CC complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with APC2 CC (PubMed:11691822). Interacts with DLG1 (via PDZ domains) and DLG3 (via CC PDZ domains) (PubMed:8638125, PubMed:9188857). Interacts with CC alpha- and beta-catenins (PubMed:8259519). Interacts with AXIN1 (via CC RGS domain) (PubMed:10811618). Interacts with ARHGEF4 (via N-terminus) CC (PubMed:10947987). Interacts (via C-terminal residues 2674-2843) with CC MAPRE1 (via C-terminal residues 206-211); the interaction inhibits CC association with and bundling of F-actin (PubMed:14514668, CC PubMed:17293347, PubMed:19632184). Interacts with MAPRE2 and MAPRE3 CC (via C-terminus) (PubMed:14514668). Interacts with DIAPH1; DIAPH1 acts CC as a scaffold protein for MAPRE1 and APC to stabilize microtubules and CC promote cell migration (By similarity). Interacts with DIAPH2 (By CC similarity). Interacts with SCRIB; may mediate APC targeting to CC adherens junctions of epithelial cells (PubMed:16611247). Interacts CC with SPATA13 (via N-terminus and SH3 domain) (PubMed:17599059). CC Interacts with ASAP1 (via SH3 domain) (PubMed:20509626). Interacts (at CC the cell membrane) with AMER1 and AMER2 (via ARM repeats) CC (PubMed:21498506, PubMed:22128170). Interacts with KHDRBS1 CC (PubMed:22000517). Interacts with actin; binds both to F-actin and CC actin filament bundles (PubMed:17293347). CC {ECO:0000250|UniProtKB:P70478, ECO:0000250|UniProtKB:Q61315, CC ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:11707392, CC ECO:0000269|PubMed:14514668, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20509626, CC ECO:0000269|PubMed:21498506, ECO:0000269|PubMed:22000517, CC ECO:0000269|PubMed:22128170, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:8259519, ECO:0000269|PubMed:8638125, CC ECO:0000269|PubMed:9188857, ECO:0000305}. CC -!- INTERACTION: CC P25054; Q5JTC6: AMER1; NbExp=4; IntAct=EBI-727707, EBI-6169747; CC P25054; Q8N944: AMER3; NbExp=8; IntAct=EBI-727707, EBI-8869590; CC P25054; Q9NR80-3: ARHGEF4; NbExp=5; IntAct=EBI-727707, EBI-13639160; CC P25054; O15169: AXIN1; NbExp=17; IntAct=EBI-727707, EBI-710484; CC P25054; O14936: CASK; NbExp=2; IntAct=EBI-727707, EBI-1215506; CC P25054; P60953: CDC42; NbExp=9; IntAct=EBI-727707, EBI-81752; CC P25054; P49674: CSNK1E; NbExp=8; IntAct=EBI-727707, EBI-749343; CC P25054; P35221: CTNNA1; NbExp=3; IntAct=EBI-727707, EBI-701918; CC P25054; P35222: CTNNB1; NbExp=22; IntAct=EBI-727707, EBI-491549; CC P25054; Q12959: DLG1; NbExp=11; IntAct=EBI-727707, EBI-357481; CC P25054; Q15700: DLG2; NbExp=2; IntAct=EBI-727707, EBI-80426; CC P25054; Q92796: DLG3; NbExp=2; IntAct=EBI-727707, EBI-80440; CC P25054; P78352: DLG4; NbExp=3; IntAct=EBI-727707, EBI-80389; CC P25054; O14640: DVL1; NbExp=6; IntAct=EBI-727707, EBI-723489; CC P25054; P54792: DVL1P1; NbExp=2; IntAct=EBI-727707, EBI-7848109; CC P25054; O14641: DVL2; NbExp=2; IntAct=EBI-727707, EBI-740850; CC P25054; Q96RT1: ERBIN; NbExp=2; IntAct=EBI-727707, EBI-993903; CC P25054; P14923: JUP; NbExp=3; IntAct=EBI-727707, EBI-702484; CC P25054; Q07666: KHDRBS1; NbExp=4; IntAct=EBI-727707, EBI-1364; CC P25054; Q14114: LRP8; NbExp=2; IntAct=EBI-727707, EBI-2681187; CC P25054; Q86UL8: MAGI2; NbExp=5; IntAct=EBI-727707, EBI-311035; CC P25054; Q15691: MAPRE1; NbExp=6; IntAct=EBI-727707, EBI-1004115; CC P25054; Q14160: SCRIB; NbExp=8; IntAct=EBI-727707, EBI-357345; CC P25054; Q96N96: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13618641; CC P25054; Q96N96-1: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13638906; CC P25054; Q96N96-2: SPATA13; NbExp=2; IntAct=EBI-727707, EBI-13639118; CC P25054; O14907: TAX1BP3; NbExp=5; IntAct=EBI-727707, EBI-723259; CC P25054; P63104: YWHAZ; NbExp=2; IntAct=EBI-727707, EBI-347088; CC P25054; Q02248: Ctnnb1; Xeno; NbExp=8; IntAct=EBI-727707, EBI-397872; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:16611247}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. Cell CC projection, lamellipodium {ECO:0000269|PubMed:19151759}. Cell CC projection, ruffle membrane {ECO:0000269|PubMed:19151759}. Cytoplasm CC {ECO:0000269|PubMed:10947987}. Cell membrane CC {ECO:0000269|PubMed:10947987, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:20937854}. Note=Associated with the microtubule CC network at the growing distal tip of microtubules (PubMed:19632184). CC MAPRE1 may be required for targeting to the growing microtubule plus CC ends (PubMed:19632184). Accumulates in the lamellipodium and ruffle CC membrane in response to hepatocyte growth factor (HGF) treatment CC (PubMed:19151759). The MEMO1-RHOA-DIAPH1 signaling pathway controls CC localization of the phosphorylated form to the cell membrane CC (PubMed:20937854). {ECO:0000269|PubMed:19151759, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1A {ECO:0000303|PubMed:19527921}; Synonyms=Long CC {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-1; Sequence=Displayed; CC Name=2; Synonyms=Short {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-2; Sequence=VSP_004115; CC Name=1B {ECO:0000303|PubMed:19527921}; CC IsoId=P25054-3; Sequence=VSP_059027, VSP_059028; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tissues: brain, small CC intestine, colon, thymus, skeletal muscle, heart, prostate, lung, CC spleen, ovary, testis kidney, placenta, blood and liver CC (PubMed:21643010, PubMed:27217144). Isoform 1A: Very strongly expressed CC in brain but has relatively low expression levels in other tissues CC (PubMed:19527921, PubMed:21643010, PubMed:27217144). Isoform 1B: CC Predominant form in all tissues except for brain, including gastric CC mucosa and blood (PubMed:19527921, PubMed:21643010, PubMed:27217144). CC {ECO:0000269|PubMed:19527921, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144}. CC -!- DOMAIN: The microtubule tip localization signal (MtLS) motif; mediates CC interaction with MAPRE1 and targeting to the growing microtubule plus CC ends. {ECO:0000250}. CC -!- DOMAIN: The basic region (residues 2167-2674) mediates the association CC with both microtubule and actin proteins and promotes the bundling of CC F-actin. {ECO:0000269|PubMed:17293347}. CC -!- PTM: Phosphorylated; phosphorylation enhances the F-actin bundling CC activity (PubMed:17293347). Phosphorylated by GSK3B. CC {ECO:0000269|PubMed:17293347}. CC -!- PTM: Ubiquitinated, leading to its degradation by the proteasome. CC Ubiquitination is facilitated by Axin. Deubiquitinated by CC ZRANB1/TRABID. {ECO:0000269|PubMed:15355978, CC ECO:0000269|PubMed:18281465}. CC -!- DISEASE: Familial adenomatous polyposis 1 (FAP1) [MIM:175100]: An CC autosomal dominant cancer predisposition syndrome characterized by CC adenomatous polyps of the colon and rectum, but also of upper CC gastrointestinal tract (ampullary, duodenal and gastric adenomas). This CC is a viciously premalignant disease with one or more polyps progressing CC through dysplasia to malignancy in untreated gene carriers with a CC median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, CC ECO:0000269|PubMed:1316610, ECO:0000269|PubMed:1338691, CC ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, CC ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144, ECO:0000269|PubMed:7661930, CC ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, CC ECO:0000269|PubMed:8111410, ECO:0000269|PubMed:8990002}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Desmoid disease, hereditary (DESMD) [MIM:135290]: An autosomal CC dominant disease characterized by multifocal fibromatosis of the CC abdominal wall and mesentery. Desmoid tumors can also affect paraspinal CC muscles, breast, occiput, arms, and lower ribs. CC {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:29753700}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric adenocarcinoma and proximal polyposis of the stomach CC (GAPPS) [MIM:619182]: A familial gastric polyposis syndrome CC characterized by autosomal dominant transmission of fundic gland CC polyposis with occasional hyperplastic and adenomatous polyps, sparing CC of the gastric antrum, and a significant risk of intestinal-type CC gastric adenocarcinoma development. Colorectal polyposis is not CC observed, and family history does not include colorectal cancer. CC {ECO:0000269|PubMed:27087319, ECO:0000269|PubMed:27343414, CC ECO:0000269|PubMed:33242120}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- MISCELLANEOUS: APC mutations have led to some interesting observations. CC (1) the great majority of the mutations found to date would result in CC truncation of the APC product. (2) almost all the mutations have CC occurred within the first half of the coding sequence, and somatic CC mutations in colorectal tumors are further clustered in a particular CC region, called MCR (mutation cluster region). (3) most identified point CC mutations in the APC gene are transitions from cytosine to other CC nucleotides. (4) the location of germline mutations tends to correlate CC with the number of colorectal polyps in FAP1 patients. Inactivation of CC both alleles of the APC gene seems to be required as an early event to CC develop most adenomas and carcinomas in the colon and rectum as well as CC some of those in the stomach. CC -!- MISCELLANEOUS: [Isoform 1B]: Produced by alternative promoter usage. CC {ECO:0000269|PubMed:19527921}. CC -!- SIMILARITY: Belongs to the adenomatous polyposis coli (APC) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases Adenomatous CC Polyposis Coli (APC); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/APC"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/118/APC"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M73548; AAA60353.1; -; mRNA. DR EMBL; M73548; AAA60354.1; -; mRNA. DR EMBL; M74088; AAA03586.1; -; mRNA. DR EMBL; AC008575; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC136500; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471086; EAW49002.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49007.1; -; Genomic_DNA. DR EMBL; AK294544; BAH11802.1; -; mRNA. DR EMBL; S78214; AAB21145.2; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS4107.1; -. [P25054-1] DR PIR; A37261; RBHUAP. DR RefSeq; NP_000029.2; NM_000038.5. [P25054-1] DR RefSeq; NP_001120982.1; NM_001127510.3. [P25054-1] DR RefSeq; NP_001120983.2; NM_001127511.3. [P25054-3] DR RefSeq; NP_001341824.1; NM_001354895.2. [P25054-1] DR RefSeq; NP_001341832.1; NM_001354903.2. [P25054-2] DR RefSeq; NP_001394379.1; NM_001407450.1. [P25054-1] DR RefSeq; NP_001394387.1; NM_001407458.1. [P25054-2] DR RefSeq; NP_001394388.1; NM_001407459.1. [P25054-2] DR RefSeq; NP_001394389.1; NM_001407460.1. [P25054-2] DR PDB; 1DEB; X-ray; 2.40 A; A/B=2-55. DR PDB; 1EMU; X-ray; 1.90 A; B=2034-2049. DR PDB; 1JPP; X-ray; 3.10 A; C/D=1021-1035. DR PDB; 1M5I; X-ray; 2.00 A; A=126-250. DR PDB; 1T08; X-ray; 2.10 A; C=1484-1498. DR PDB; 1TH1; X-ray; 2.50 A; C/D=1362-1540. DR PDB; 1V18; X-ray; 2.10 A; B=1482-1528. DR PDB; 2RQU; NMR; -; B=1578-1596. DR PDB; 3AU3; X-ray; 2.10 A; A=396-732. DR PDB; 3NMW; X-ray; 1.60 A; A/B=407-751. DR PDB; 3NMX; X-ray; 2.30 A; A/B/C=407-751. DR PDB; 3NMZ; X-ray; 3.01 A; A/B=303-739. DR PDB; 3QHE; X-ray; 2.40 A; A/C=396-732. DR PDB; 3RL7; X-ray; 2.30 A; G/H/I/J/K/L=2833-2843. DR PDB; 3RL8; X-ray; 2.20 A; F=2833-2843. DR PDB; 3T7U; X-ray; 2.90 A; A/B=407-775. DR PDB; 4G69; X-ray; 2.00 A; B=2833-2843. DR PDB; 4YJE; X-ray; 1.90 A; A=407-751. DR PDB; 4YJL; X-ray; 2.10 A; A/B/C/D/E/F=407-751. DR PDB; 4YK6; X-ray; 1.70 A; A=407-751. DR PDB; 5B6G; X-ray; 1.99 A; A=407-751. DR PDB; 5IZ6; X-ray; 2.15 A; A=407-751. DR PDB; 5IZ8; X-ray; 3.06 A; A/B=407-751. DR PDB; 5IZ9; X-ray; 2.93 A; A=407-751. DR PDB; 5IZA; X-ray; 1.50 A; A=407-751. DR PDB; 5Z8H; X-ray; 1.79 A; A=407-741. DR PDB; 7F6M; X-ray; 2.40 A; A=407-751. DR PDB; 7F7O; X-ray; 2.80 A; A=407-738. DR PDB; 7XTY; X-ray; 2.10 A; C/D=2833-2843. DR PDB; 8GSJ; X-ray; 2.10 A; A=407-738. DR PDB; 8X2Q; X-ray; 2.00 A; A=126-250. DR PDBsum; 1DEB; -. DR PDBsum; 1EMU; -. DR PDBsum; 1JPP; -. DR PDBsum; 1M5I; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 1V18; -. DR PDBsum; 2RQU; -. DR PDBsum; 3AU3; -. DR PDBsum; 3NMW; -. DR PDBsum; 3NMX; -. DR PDBsum; 3NMZ; -. DR PDBsum; 3QHE; -. DR PDBsum; 3RL7; -. DR PDBsum; 3RL8; -. DR PDBsum; 3T7U; -. DR PDBsum; 4G69; -. DR PDBsum; 4YJE; -. DR PDBsum; 4YJL; -. DR PDBsum; 4YK6; -. DR PDBsum; 5B6G; -. DR PDBsum; 5IZ6; -. DR PDBsum; 5IZ8; -. DR PDBsum; 5IZ9; -. DR PDBsum; 5IZA; -. DR PDBsum; 5Z8H; -. DR PDBsum; 7F6M; -. DR PDBsum; 7F7O; -. DR PDBsum; 7XTY; -. DR PDBsum; 8GSJ; -. DR PDBsum; 8X2Q; -. DR BMRB; P25054; -. DR SMR; P25054; -. DR BioGRID; 106821; 370. DR ComplexPortal; CPX-107; Beta-catenin destruction core complex, APC-AXIN1-GSK3A variant. DR ComplexPortal; CPX-109; Beta-catenin destruction core complex, APC-AXIN1-GSK3B variant. DR ComplexPortal; CPX-439; Beta-catenin destruction core complex, APC-AXIN2-GSK3B variant. DR ComplexPortal; CPX-441; Beta-catenin destruction core complex, APC-AXIN2-GSK3A variant. DR CORUM; P25054; -. DR DIP; DIP-33556N; -. DR FunCoup; P25054; 1537. DR IntAct; P25054; 301. DR MINT; P25054; -. DR STRING; 9606.ENSP00000257430; -. DR BindingDB; P25054; -. DR ChEMBL; CHEMBL3233; -. DR GlyCosmos; P25054; 3 sites, 2 glycans. DR GlyGen; P25054; 8 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (4 sites). DR iPTMnet; P25054; -. DR PhosphoSitePlus; P25054; -. DR BioMuta; APC; -. DR DMDM; 97535708; -. DR jPOST; P25054; -. DR MassIVE; P25054; -. DR PaxDb; 9606-ENSP00000257430; -. DR PeptideAtlas; P25054; -. DR ProteomicsDB; 54247; -. [P25054-1] DR ProteomicsDB; 54248; -. [P25054-2] DR ProteomicsDB; 6428; -. DR Pumba; P25054; -. DR Antibodypedia; 1054; 757 antibodies from 45 providers. DR DNASU; 324; -. DR Ensembl; ENST00000257430.9; ENSP00000257430.4; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000507379.6; ENSP00000423224.2; ENSG00000134982.20. [P25054-3] DR Ensembl; ENST00000508376.6; ENSP00000427089.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000509732.6; ENSP00000426541.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000512211.7; ENSP00000423828.3; ENSG00000134982.20. [P25054-1] DR GeneID; 324; -. DR KEGG; hsa:324; -. DR MANE-Select; ENST00000257430.9; ENSP00000257430.4; NM_000038.6; NP_000029.2. DR UCSC; uc003kpy.5; human. [P25054-1] DR UCSC; uc063gan.1; human. DR AGR; HGNC:583; -. DR CIViC; 324; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA24875; -. DR CTD; 324; -. DR DisGeNET; 324; -. DR GeneCards; APC; -. DR GeneReviews; APC; -. DR HGNC; HGNC:583; APC. DR HPA; ENSG00000134982; Tissue enhanced (brain). DR MalaCards; APC; -. DR MIM; 114550; phenotype. DR MIM; 135290; phenotype. DR MIM; 155255; phenotype. DR MIM; 175100; phenotype. DR MIM; 611731; gene. DR MIM; 613659; phenotype. DR MIM; 619182; phenotype. DR OpenTargets; ENSG00000134982; -. DR Orphanet; 261584; 5q22 microdeletion syndrome. DR Orphanet; 220460; Attenuated familial adenomatous polyposis. DR Orphanet; 3258; Cenani-Lenz syndrome. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 314022; Gastric adenocarcinoma and proximal polyposis of the stomach. DR VEuPathDB; HostDB:ENSG00000134982; -. DR eggNOG; KOG2122; Eukaryota. DR GeneTree; ENSGT00530000063749; -. DR HOGENOM; CLU_001012_0_0_1; -. DR InParanoid; P25054; -. DR OMA; DHEKHSP; -. DR OrthoDB; 5918429at2759; -. DR PAN-GO; P25054; 14 GO annotations based on evolutionary models. DR PhylomeDB; P25054; -. DR BioCyc; MetaCyc:ENSG00000134982-MONOMER; -. DR PathwayCommons; P25054; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5467333; APC truncation mutants are not K63 polyubiquitinated. DR Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding. DR Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex. DR Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR SignaLink; P25054; -. DR SIGNOR; P25054; -. DR Agora; ENSG00000134982; -. DR BioGRID-ORCS; 324; 172 hits in 1170 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D8D47D1F; Synthetic Condensate 000297. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; APC; human. DR EvolutionaryTrace; P25054; -. DR GeneWiki; Adenomatous_polyposis_coli; -. DR GenomeRNAi; 324; -. DR Pharos; P25054; Tchem. DR PRO; PR:P25054; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P25054; protein. DR Bgee; ENSG00000134982; Expressed in substantia nigra pars compacta and 207 other cell types or tissues. DR ExpressionAtlas; P25054; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:CACAO. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0070840; F:dynein complex binding; IPI:CAFA. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0051010; F:microtubule plus-end binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IDA:DisProt. DR GO; GO:0019887; F:protein kinase regulator activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:MGI. DR GO; GO:0070830; P:bicellular tight junction assembly; NAS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; NAS:UniProtKB. DR GO; GO:0001708; P:cell fate specification; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0003170; P:heart valve development; ISS:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:MGI. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:MGI. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:MGI. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IGI:MGI. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:CAFA. DR GO; GO:0031274; P:positive regulation of pseudopodium assembly; IMP:MGI. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; NAS:ComplexPortal. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:MGI. DR GO; GO:0060632; P:regulation of microtubule-based movement; IEP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IMP:UniProtKB. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR DisProt; DP00519; -. DR FunFam; 1.25.10.10:FF:000035; adenomatous polyposis coli protein 2; 1. DR FunFam; 1.10.287.450:FF:000001; adenomatous polyposis coli protein isoform X1; 1. DR Gene3D; 1.20.5.10; -; 1. DR Gene3D; 1.10.287.450; Helix hairpin bin; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00035; -. DR InterPro; IPR009240; APC_15aa_rpt. DR InterPro; IPR009234; APC_basic_dom. DR InterPro; IPR026831; APC_dom. DR InterPro; IPR026818; Apc_fam. DR InterPro; IPR032038; APC_N. DR InterPro; IPR036149; APC_N_sf. DR InterPro; IPR041257; APC_rep. DR InterPro; IPR009223; APC_rpt. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR009232; EB1-bd. DR InterPro; IPR009224; SAMP. DR PANTHER; PTHR12607:SF11; ADENOMATOUS POLYPOSIS COLI PROTEIN; 1. DR PANTHER; PTHR12607; ADENOMATOUS POLYPOSIS COLI PROTEIN FAMILY; 1. DR Pfam; PF05972; APC_15aa; 4. DR Pfam; PF05956; APC_basic; 1. DR Pfam; PF16689; APC_N_CC; 1. DR Pfam; PF05923; APC_r; 7. DR Pfam; PF18797; APC_rep; 1. DR Pfam; PF16634; APC_u13; 1. DR Pfam; PF16635; APC_u14; 1. DR Pfam; PF16636; APC_u15; 1. DR Pfam; PF16630; APC_u5; 1. DR Pfam; PF16633; APC_u9; 1. DR Pfam; PF00514; Arm; 3. DR Pfam; PF16629; Arm_APC_u3; 1. DR Pfam; PF05937; EB1_binding; 1. DR Pfam; PF05924; SAMP; 3. DR Pfam; PF11414; Suppressor_APC; 1. DR SMART; SM00185; ARM; 7. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF58050; N-terminal coiled coil domain from apc; 1. DR SUPFAM; SSF82931; Tumor suppressor gene product Apc; 1. DR PROSITE; PS50176; ARM_REPEAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; KW Alternative splicing; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; Membrane; KW Microtubule; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Tumor suppressor; Ubl conjugation; Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..2843 FT /note="Adenomatous polyposis coli protein" FT /id="PRO_0000064627" FT REPEAT 453..495 FT /note="ARM 1" FT REPEAT 505..547 FT /note="ARM 2" FT REPEAT 548..591 FT /note="ARM 3" FT REPEAT 592..638 FT /note="ARM 4" FT REPEAT 639..683 FT /note="ARM 5" FT REPEAT 684..725 FT /note="ARM 6" FT REPEAT 726..767 FT /note="ARM 7" FT REGION 239..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..878 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 923..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 958..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 960..1337 FT /note="Responsible for down-regulation through a process FT mediated by direct ubiquitination" FT REGION 1020..1169 FT /note="Interaction with catenins" FT /evidence="ECO:0000269|PubMed:8259519" FT REGION 1099..1169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1190..1244 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1311..1376 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1403..1475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1526..1569 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1583..1611 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1664..1717 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1729..1836 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1893 FT /note="Highly charged" FT REGION 1881..1950 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1965..2011 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2035..2059 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000269|PubMed:10811618" FT REGION 2043..2072 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2147..2635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2167..2674 FT /note="Basic region" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2475..2843 FT /note="Interaction with DLG1" FT /evidence="ECO:0000269|PubMed:8638125" FT REGION 2667..2714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2674..2843 FT /note="Interaction with MAPRE1" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2729..2843 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 2..61 FT /evidence="ECO:0000255" FT COILED 127..248 FT /evidence="ECO:0000255" FT MOTIF 2803..2806 FT /note="Microtubule tip localization signal" FT MOTIF 2841..2843 FT /note="PDZ-binding" FT COMPBIAS 241..261 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..282 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 290..299 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 833..843 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 844..857 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 869..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 927..943 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 961..971 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1107..1130 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1146..1159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1190..1224 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1225..1244 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1335..1345 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1355..1366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1448..1466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1540..1564 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1683..1698 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1735..1744 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1785..1794 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1804..1813 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1881..1896 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1897..1913 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1928..1938 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1939..1950 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1979..1991 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2169..2187 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2203..2223 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2257..2271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2286..2331 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2348..2369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2370..2409 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2418..2427 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2459..2477 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2518..2535 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2555..2568 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2569..2579 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2580..2592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2593..2608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2620..2635 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2668..2679 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2741..2757 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2763..2774 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2784..2812 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 107 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 744 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 748 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 908 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1038 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1392 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1438 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1774 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1863 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1971 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1973 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2088 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2093 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2125 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2129 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2132 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2151 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2260 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2283 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2473 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2535 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2569 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2671 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2679 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2710 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..45 FT /note="MAAASYDQLLKQVEALKMENSNLRQELEDNSNHLTKLETEASNMK -> MYA FT SLGSGPVAPLPASVPPSVLGSWSTGGSRSCVRQETKSPGGARTSGHWASVWQ (in FT isoform 1B)" FT /id="VSP_059027" FT VAR_SEQ 217..244 FT /note="Missing (in isoform 1B)" FT /id="VSP_059028" FT VAR_SEQ 312..412 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:1678319" FT /id="VSP_004115" FT VARIANT 99 FT /note="R -> W (in FAP1; benign; dbSNP:rs139196838)" FT /evidence="ECO:0000269|PubMed:7833149" FT /id="VAR_009613" FT VARIANT 171 FT /note="S -> I (in FAP1)" FT /evidence="ECO:0000269|PubMed:8990002" FT /id="VAR_005032" FT VARIANT 414 FT /note="R -> C (in FAP1; benign; dbSNP:rs137854567)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005033" FT VARIANT 722 FT /note="S -> G (in FAP1)" FT /evidence="ECO:0000269|PubMed:7833931" FT /id="VAR_009614" FT VARIANT 784 FT /note="S -> T (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005034" FT VARIANT 817 FT /note="G -> C (in gastric cancer)" FT /id="VAR_005035" FT VARIANT 870 FT /note="P -> S (in dbSNP:rs33974176)" FT /id="VAR_053976" FT VARIANT 880 FT /note="I -> T (in colorectal carcinoma and gastric cancer; FT from a patient with MMRCS; dbSNP:rs1400295986)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_005036" FT VARIANT 890 FT /note="V -> I (in colorectal carcinoma; from a patient with FT MMRCS; dbSNP:rs779998847)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012975" FT VARIANT 906 FT /note="S -> Y (in colorectal tumor)" FT /id="VAR_005037" FT VARIANT 911 FT /note="E -> G (in FAP1 and colorectal tumor)" FT /evidence="ECO:0000269|PubMed:1338904" FT /id="VAR_005038" FT VARIANT 942 FT /note="N -> D (in gastric cancer)" FT /id="VAR_005039" FT VARIANT 1027 FT /note="Y -> C (in colorectal tumor; dbSNP:rs869312784)" FT /id="VAR_005040" FT VARIANT 1057 FT /note="E -> G (found in a family whose members exhibit FT gastrointestinal cancers and multiple pigmented cutaneous FT lesions; uncertain significance)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_009615" FT VARIANT 1118 FT /note="N -> D (in dbSNP:rs140493115)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005041" FT VARIANT 1120 FT /note="G -> E (in gastric cancer; dbSNP:rs28933379)" FT /id="VAR_005042" FT VARIANT 1171 FT /note="R -> C (in dbSNP:rs201830995)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008992" FT VARIANT 1171 FT /note="R -> H (in gastric cancer; dbSNP:rs372481703)" FT /id="VAR_005043" FT VARIANT 1176 FT /note="P -> L (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005044" FT VARIANT 1184 FT /note="A -> P (in FAP1)" FT /evidence="ECO:0000269|PubMed:10470088" FT /id="VAR_009616" FT VARIANT 1197 FT /note="F -> S (in gastric cancer)" FT /id="VAR_005045" FT VARIANT 1254 FT /note="I -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035794" FT VARIANT 1259 FT /note="I -> T (in gastric cancer)" FT /id="VAR_005046" FT VARIANT 1292 FT /note="T -> M (in FAP1; uncertain significance; FT dbSNP:rs371113837)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005047" FT VARIANT 1296 FT /note="A -> V (in MDB; sporadic; dbSNP:rs1291513037)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017653" FT VARIANT 1304 FT /note="I -> V (in dbSNP:rs770157475)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005048" FT VARIANT 1307 FT /note="I -> K (probable risk factor for colon and breast FT cancer; dbSNP:rs1801155)" FT /evidence="ECO:0000269|PubMed:9724771, FT ECO:0000269|PubMed:9731522, ECO:0000269|PubMed:9731533, FT ECO:0000269|PubMed:9973276" FT /id="VAR_005049" FT VARIANT 1312 FT /note="G -> E (in gastric cancer)" FT /id="VAR_005050" FT VARIANT 1313 FT /note="T -> A (in FAP1 and colorectal tumor; FT dbSNP:rs863225349)" FT /id="VAR_005051" FT VARIANT 1317 FT /note="E -> Q (may contribute to colorectal tumor FT development; dbSNP:rs1801166)" FT /evidence="ECO:0000269|PubMed:9724771" FT /id="VAR_009617" FT VARIANT 1326 FT /note="V -> A (in gastric cancer)" FT /id="VAR_005052" FT VARIANT 1348 FT /note="R -> W (in FAP1)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005053" FT VARIANT 1395 FT /note="S -> C (in hepatoblastoma; dbSNP:rs137854578)" FT /evidence="ECO:0000269|PubMed:8764128" FT /id="VAR_065133" FT VARIANT 1422 FT /note="D -> H (in colorectal tumor)" FT /id="VAR_005054" FT VARIANT 1472 FT /note="V -> I (in MDB; sporadic; dbSNP:rs878853445)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017654" FT VARIANT 1495 FT /note="S -> G (in MDB; sporadic)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017655" FT VARIANT 1496 FT /note="T -> S (in dbSNP:rs2229996)" FT /id="VAR_020141" FT VARIANT 1508 FT /note="A -> V (in colorectal carcinoma from a patient with FT MMRCS)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012976" FT VARIANT 1822 FT /note="V -> D (in dbSNP:rs459552)" FT /evidence="ECO:0000269|PubMed:1651562, FT ECO:0000269|PubMed:1678319, ECO:0000269|PubMed:9950360, FT ECO:0000269|Ref.5" FT /id="VAR_008993" FT VARIANT 1882 FT /note="R -> T (in dbSNP:rs34157245)" FT /id="VAR_053977" FT VARIANT 1973 FT /note="S -> T (in dbSNP:rs4987109)" FT /id="VAR_020142" FT VARIANT 2499 FT /note="V -> L (in dbSNP:rs33941929)" FT /id="VAR_053978" FT VARIANT 2502 FT /note="G -> S (in dbSNP:rs2229995)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005055" FT VARIANT 2621 FT /note="S -> C (in FAP1; benign; dbSNP:rs72541816)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005056" FT VARIANT 2738 FT /note="I -> T (in dbSNP:rs863224552)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008994" FT VARIANT 2839 FT /note="L -> F (in FAP1; dbSNP:rs876658156)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005057" FT MUTAGEN 516 FT /note="K->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 549 FT /note="R->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 2841 FT /note="T->L: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT MUTAGEN 2843 FT /note="V->Q: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT CONFLICT 184 FT /note="M -> L (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 970 FT /note="S -> N (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1309 FT /note="E -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1325..1331 FT /note="AVSQHPR -> SSVHSTLE (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1355 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1591 FT /note="A -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2723 FT /note="N -> T (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2755 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT HELIX 6..53 FT /evidence="ECO:0007829|PDB:1DEB" FT HELIX 132..169 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:8X2Q" FT HELIX 180..204 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 208..238 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 328..338 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 343..350 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 353..360 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 377..393 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 407..426 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:3AU3" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 446..456 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 460..468 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 471..486 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 492..509 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 513..521 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 523..531 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 532..534 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 538..552 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 557..565 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 568..578 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 582..596 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 600..607 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 612..619 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 625..627 FT /evidence="ECO:0007829|PDB:3NMW" FT HELIX 629..646 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 650..658 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 661..668 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 674..687 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 688..690 FT /evidence="ECO:0007829|PDB:5IZ8" FT HELIX 692..700 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 703..708 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 709..712 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 716..731 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 739..742 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 1027..1030 FT /evidence="ECO:0007829|PDB:1JPP" FT HELIX 1470..1479 FT /evidence="ECO:0007829|PDB:1TH1" FT HELIX 1520..1524 FT /evidence="ECO:0007829|PDB:1V18" FT HELIX 2036..2045 FT /evidence="ECO:0007829|PDB:1EMU" FT STRAND 2841..2843 FT /evidence="ECO:0007829|PDB:7XTY" SQ SEQUENCE 2843 AA; 311646 MW; 77E194AE4A91DC5A CRC64; MAAASYDQLL KQVEALKMEN SNLRQELEDN SNHLTKLETE ASNMKEVLKQ LQGSIEDEAM ASSGQIDLLE RLKELNLDSS NFPGVKLRSK MSLRSYGSRE GSVSSRSGEC SPVPMGSFPR RGFVNGSRES TGYLEELEKE RSLLLADLDK EEKEKDWYYA QLQNLTKRID SLPLTENFSL QTDMTRRQLE YEARQIRVAM EEQLGTCQDM EKRAQRRIAR IQQIEKDILR IRQLLQSQAT EAERSSQNKH ETGSHDAERQ NEGQGVGEIN MATSGNGQGS TTRMDHETAS VLSSSSTHSA PRRLTSHLGT KVEMVYSLLS MLGTHDKDDM SRTLLAMSSS QDSCISMRQS GCLPLLIQLL HGNDKDSVLL GNSRGSKEAR ARASAALHNI IHSQPDDKRG RREIRVLHLL EQIRAYCETC WEWQEAHEPG MDQDKNPMPA PVEHQICPAV CVLMKLSFDE EHRHAMNELG GLQAIAELLQ VDCEMYGLTN DHYSITLRRY AGMALTNLTF GDVANKATLC SMKGCMRALV AQLKSESEDL QQVIASVLRN LSWRADVNSK KTLREVGSVK ALMECALEVK KESTLKSVLS ALWNLSAHCT ENKADICAVD GALAFLVGTL TYRSQTNTLA IIESGGGILR NVSSLIATNE DHRQILRENN CLQTLLQHLK SHSLTIVSNA CGTLWNLSAR NPKDQEALWD MGAVSMLKNL IHSKHKMIAM GSAAALRNLM ANRPAKYKDA NIMSPGSSLP SLHVRKQKAL EAELDAQHLS ETFDNIDNLS PKASHRSKQR HKQSLYGDYV FDTNRHDDNR SDNFNTGNMT VLSPYLNTTV LPSSSSSRGS LDSSRSEKDR SLERERGIGL GNYHPATENP GTSSKRGLQI STTAAQIAKV MEEVSAIHTS QEDRSSGSTT ELHCVTDERN ALRRSSAAHT HSNTYNFTKS ENSNRTCSMP YAKLEYKRSS NDSLNSVSSS DGYGKRGQMK PSIESYSEDD ESKFCSYGQY PADLAHKIHS ANHMDDNDGE LDTPINYSLK YSDEQLNSGR QSPSQNERWA RPKHIIEDEI KQSEQRQSRN QSTTYPVYTE STDDKHLKFQ PHFGQQECVS PYRSRGANGS ETNRVGSNHG INQNVSQSLC QEDDYEDDKP TNYSERYSEE EQHEEEERPT NYSIKYNEEK RHVDQPIDYS LKYATDIPSS QKQSFSFSKS SSGQSSKTEH MSSSSENTST PSSNAKRQNQ LHPSSAQSRS GQPQKAATCK VSSINQETIQ TYCVEDTPIC FSRCSSLSSL SSAEDEIGCN QTTQEADSAN TLQIAEIKEK IGTRSAEDPV SEVPAVSQHP RTKSSRLQGS SLSSESARHK AVEFSSGAKS PSKSGAQTPK SPPEHYVQET PLMFSRCTSV SSLDSFESRS IASSVQSEPC SGMVSGIISP SDLPDSPGQT MPPSRSKTPP PPPQTAQTKR EVPKNKAPTA EKRESGPKQA AVNAAVQRVQ VLPDADTLLH FATESTPDGF SCSSSLSALS LDEPFIQKDV ELRIMPPVQE NDNGNETESE QPKESNENQE KEAEKTIDSE KDLLDDSDDD DIEILEECII SAMPTKSSRK AKKPAQTASK LPPPVARKPS QLPVYKLLPS QNRLQPQKHV SFTPGDDMPR VYCVEGTPIN FSTATSLSDL TIESPPNELA AGEGVRGGAQ SGEFEKRDTI PTEGRSTDEA QGGKTSSVTI PELDDNKAEE GDILAECINS AMPKGKSHKP FRVKKIMDQV QQASASSSAP NKNQLDGKKK KPTSPVKPIP QNTEYRTRVR KNADSKNNLN AERVFSDNKD SKKQNLKNNS KVFNDKLPNN EDRVRGSFAF DSPHHYTPIE GTPYCFSRND SLSSLDFDDD DVDLSREKAE LRKAKENKES EAKVTSHTEL TSNQQSANKT QAIAKQPINR GQPKPILQKQ STFPQSSKDI PDRGAATDEK LQNFAIENTP VCFSHNSSLS SLSDIDQENN NKENEPIKET EPPDSQGEPS KPQASGYAPK SFHVEDTPVC FSRNSSLSSL SIDSEDDLLQ ECISSAMPKK KKPSRLKGDN EKHSPRNMGG ILGEDLTLDL KDIQRPDSEH GLSPDSENFD WKAIQEGANS IVSSLHQAAA AACLSRQASS DSDSILSLKS GISLGSPFHL TPDQEEKPFT SNKGPRILKP GEKSTLETKK IESESKGIKG GKKVYKSLIT GKVRSNSEIS GQMKQPLQAN MPSISRGRTM IHIPGVRNSS SSTSPVSKKG PPLKTPASKS PSEGQTATTS PRGAKPSVKS ELSPVARQTS QIGGSSKAPS RSGSRDSTPS RPAQQPLSRP IQSPGRNSIS PGRNGISPPN KLSQLPRTSS PSTASTKSSG SGKMSYTSPG RQMSQQNLTK QTGLSKNASS IPRSESASKG LNQMNNGNGA NKKVELSRMS STKSSGSESD RSERPVLVRQ STFIKEAPSP TLRRKLEESA SFESLSPSSR PASPTRSQAQ TPVLSPSLPD MSLSTHSSVQ AGGWRKLPPN LSPTIEYNDG RPAKRHDIAR SHSESPSRLP INRSGTWKRE HSKHSSSLPR VSTWRRTGSS SSILSASSES SEKAKSEDEK HVNSISGTKQ SKENQVSAKG TWRKIKENEF SPTNSTSQTV SSGATNGAES KTLIYQMAPA VSKTEDVWVR IEDCPINNPR SGRSPTGNTP PVIDSVSEKA NPNIKDSKDN QAKQNVGNGS VPMRTVGLEN RLNSFIQVDA PDQKGTEIKP GQNNPVPVSE TNESSIVERT PFSSSSSSKH SSPSGTVAAR VTPFNYNPSP RKSSADSTSA RPSQIPTPVN NNTKKRDSKT DSTESSGTQS PKRHSGSYLV TSV // ID PK3CA_HUMAN Reviewed; 1068 AA. AC P42336; Q14CW1; Q99762; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 2. DT 28-JAN-2026, entry version 242. DE RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; DE Short=PI3-kinase subunit alpha; DE Short=PI3K-alpha; DE Short=PI3Kalpha {ECO:0000303|PubMed:28676499}; DE Short=PtdIns-3-kinase subunit alpha; DE EC=2.7.1.137 {ECO:0000269|PubMed:23936502}; DE EC=2.7.1.153 {ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; DE AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; DE Short=PtdIns-3-kinase subunit p110-alpha; DE Short=p110alpha {ECO:0000303|PubMed:15135396}; DE AltName: Full=Phosphoinositide 3-kinase alpha {ECO:0000303|PubMed:28676499}; DE AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide; DE AltName: Full=Serine/threonine protein kinase PIK3CA; DE EC=2.7.11.1 {ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; GN Name=PIK3CA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332. RX PubMed=7713498; DOI=10.1006/geno.1994.1655; RA Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R., Rocchi M., RA Waterfield M.; RT "Molecular cloning, cDNA sequence, and chromosomal localization of the RT human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene."; RL Genomics 24:472-477(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9043658; DOI=10.1016/s0968-0896(96)00196-4; RA Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M., RA Oliff A., Heimbrook D.C.; RT "Cloning and mutagenesis of the p110 alpha subunit of human RT phosphoinositide 3'-hydroxykinase."; RL Bioorg. Med. Chem. 5:65-74(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH APPL1. RX PubMed=10490823; DOI=10.1038/sj.onc.1203080; RA Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A., Testa J.R.; RT "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor RT molecule that interacts with the oncoprotein-serine/threonine kinase RT AKT2."; RL Oncogene 18:4891-4898(1999). RN [5] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15135396; DOI=10.1016/j.pep.2003.12.010; RA Meier T.I., Cook J.A., Thomas J.E., Radding J.A., Horn C., Lingaraj T., RA Smith M.C.; RT "Cloning, expression, purification, and characterization of the human Class RT Ia phosphoinositide 3-kinase isoforms."; RL Protein Expr. Purif. 35:218-224(2004). RN [6] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23936502; DOI=10.1371/journal.pone.0071337; RA Buchanan C.M., Dickson J.M., Lee W.J., Guthridge M.A., Kendall J.D., RA Shepherd P.R.; RT "Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its RT protein kinase activity."; RL PLoS ONE 8:e71337-e71337(2013). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=28676499; DOI=10.1074/jbc.m116.772426; RA Maheshwari S., Miller M.S., O'Meally R., Cole R.N., Amzel L.M., RA Gabelli S.B.; RT "Kinetic and structural analyses reveal residues in phosphoinositide 3- RT kinase alpha that are critical for catalysis and substrate recognition."; RL J. Biol. Chem. 292:13541-13550(2017). RN [8] RP FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS LYS-545 RP AND ARG-1047. RX PubMed=21708979; DOI=10.1083/jcb.201009126; RA Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M., Kouchi Z., RA Nakamura Y., Sakai R., Fukami K.; RT "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} RT regulates invadopodia formation."; RL J. Cell Biol. 193:1275-1288(2011). RN [9] RP INVOLVEMENT IN MADAC, AND VARIANTS MADAC PRO-115; LYS-542; ARG-1047 AND RP LEU-1047. RX PubMed=23100325; DOI=10.1093/hmg/dds440; RA Rios J.J., Paria N., Burns D.K., Israel B.A., Cornelia R., Wise C.A., RA Ezaki M.; RT "Somatic gain-of-function mutations in PIK3CA in patients with RT macrodactyly."; RL Hum. Mol. Genet. 22:444-451(2013). RN [10] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [11] RP REVIEW ON CANCER. RX PubMed=18418043; DOI=10.4161/cc.7.9.5817; RA Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.; RT "Insights into the oncogenic effects of PIK3CA mutations from the structure RT of p110alpha/p85alpha."; RL Cell Cycle 7:1151-1156(2008). RN [12] RP REVIEW ON FUNCTION, AND REVIEW ON CANCER. RX PubMed=18794883; DOI=10.1038/onc.2008.244; RA Zhao L., Vogt P.K.; RT "Class I PI3K in oncogenic cellular transformation."; RL Oncogene 27:5486-5496(2008). RN [13] RP REVIEW ON FUNCTION. RX PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007; RA Jia S., Roberts T.M., Zhao J.J.; RT "Should individual PI3 kinase isoforms be targeted in cancer?"; RL Curr. Opin. Cell Biol. 21:199-208(2009). RN [14] RP INVOLVEMENT IN CLAPO, AND VARIANTS CLAPO SER-83; PRO-115; ARG-420; LYS-542 RP AND LEU-1047. RX PubMed=29446767; DOI=10.1038/gim.2017.200; RA Rodriguez-Laguna L., Ibanez K., Gordo G., Garcia-Minaur S., RA Santos-Simarro F., Agra N., Vallespin E., Fernandez-Montano V.E., RA Martin-Arenas R., Del Pozo A., Gonzalez-Pecellin H., Mena R., RA Rueda-Arenas I., Gomez M.V., Villaverde C., Bustamante A., Ayuso C., RA Ruiz-Perez V.L., Nevado J., Lapunzina P., Lopez-Gutierrez J.C., RA Martinez-Glez V.; RT "CLAPO syndrome: identification of somatic activating PIK3CA mutations and RT delineation of the natural history and phenotype."; RL Genet. Med. 20:882-889(2018). RN [15] RP INVOLVEMENT IN CCM4, AND VARIANTS CCM4 LYS-542; ARG-1047 AND LEU-1047. RX PubMed=34496175; DOI=10.1056/nejmoa2100440; RA Peyre M., Miyagishima D., Bielle F., Chapon F., Sierant M., Venot Q., RA Lerond J., Marijon P., Abi-Jaoude S., Le Van T., Labreche K., Houlston R., RA Faisant M., Clemenceau S., Boch A.L., Nouet A., Carpentier A., Boetto J., RA Louvi A., Kalamarides M.; RT "Somatic PIK3CA mutations in sporadic cerebral cavernous malformations."; RL N. Engl. J. Med. 385:996-996(2021). RN [16] RP INVOLVEMENT IN HFMH, VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047, AND RP CHARACTERIZATION OF VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047. RX PubMed=37712948; DOI=10.1084/jem.20230926; RA Bayard C., Segna E., Taverne M., Fraissenon A., Hennocq Q., Periou B., RA Zerbib L., Ladraa S., Chapelle C., Hoguin C., Kaltenbach S., Villarese P., RA Asnafi V., Broissand C., Nemazanyy I., Autret G., Goudin N., Legendre C., RA Authier F.J., Viel T., Tavitian B., Gitiaux C., Fraitag S., Duong J.P., RA Delcros C., Sergent B., Picard A., Dussiot M., Guibaud L., Khonsari R., RA Canaud G.; RT "Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of- RT function mutations and responds to pharmacological inhibition."; RL J. Exp. Med. 220:0-0(2023). RN [17] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND DOMAINS. RX PubMed=18079394; DOI=10.1126/science.1150799; RA Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., RA Kinzler K.W., Vogelstein B., Gabelli S.B., Amzel L.M.; RT "The structure of a human p110alpha/p85alpha complex elucidates the effects RT of oncogenic PI3Kalpha mutations."; RL Science 318:1744-1748(2007). RN [18] RP STRUCTURE BY NMR OF 331-481. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C2 domain from human PI3-kinase p110 subunit RT alpha."; RL Submitted (APR-2008) to the PDB data bank. RN [19] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH RP WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION OF VARIANT RP ARG-1047, AND DOMAINS. RX PubMed=19805105; DOI=10.1073/pnas.0908444106; RA Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., RA Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.; RT "A frequent kinase domain mutation that changes the interaction between RT PI3Kalpha and the membrane."; RL Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009). RN [20] RP VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND RP TYR-1065. RX PubMed=15289301; DOI=10.1158/0008-5472.can-04-1170; RA Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., RA McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.; RT "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade RT astrocytomas, and medulloblastomas."; RL Cancer Res. 64:5048-5050(2004). RN [21] RP INVOLVEMENT IN OC, AND VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; RP ARG-1047 AND LEU-1047. RX PubMed=15520168; DOI=10.1158/0008-5472.can-04-2933; RA Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., RA Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A.; RT "Mutation of the PIK3CA gene in ovarian and breast cancer."; RL Cancer Res. 64:7678-7681(2004). RN [22] RP VARIANT CANCER ARG-1047. RX PubMed=15016963; DOI=10.1126/science.1096502; RA Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., RA Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V., Markowitz S., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "High frequency of mutations of the PIK3CA gene in human cancers."; RL Science 304:554-554(2004). RN [23] RP VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025. RX PubMed=15924253; DOI=10.1007/s00401-005-1000-1; RA Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.; RT "PIK3CA mutations in glioblastoma multiforme."; RL Acta Neuropathol. 109:639-642(2005). RN [24] RP VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=15784156; DOI=10.1186/1471-2407-5-29; RA Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M., So S., RA Chen X., Yuen S.T., Leung S.Y.; RT "Mutations of PIK3CA in gastric adenocarcinoma."; RL BMC Cancer 5:29-29(2005). RN [25] RP INVOLVEMENT IN CRC, AND CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; RP ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047. RX PubMed=15930273; DOI=10.1158/0008-5472.can-04-4114; RA Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., RA Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M., Kawabe T., RA Omata M.; RT "Functional analysis of PIK3CA gene mutations in human colorectal cancer."; RL Cancer Res. 65:4562-4567(2005). RN [26] RP VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; RP CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND RP LEU-1065. RX PubMed=16322209; DOI=10.1158/0008-5472.can-05-2620; RA Oda K., Stokoe D., Taketani Y., McCormick F.; RT "High frequency of coexistent mutations of PIK3CA and PTEN genes in RT endometrial carcinoma."; RL Cancer Res. 65:10669-10673(2005). RN [27] RP INVOLVEMENT IN CRC, AND VARIANTS CANCER LYS-542; GLY-545; LYS-545; RP GLN-1023; ARG-1047 AND LEU-1047. RX PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022; RA Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., RA Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R., RA Seruca R.; RT "The prevalence of PIK3CA mutations in gastric and colon cancer."; RL Eur. J. Cancer 41:1649-1654(2005). RN [28] RP VARIANTS CANCER LYS-545 AND ARG-1047. RX PubMed=15712344; DOI=10.1002/humu.9316; RA Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.; RT "PIK3CA mutations in advanced ovarian carcinomas."; RL Hum. Mutat. 25:322-322(2005). RN [29] RP VARIANT HCC ALA-545. RX PubMed=15608678; DOI=10.1038/sj.onc.1208304; RA Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., RA Lee J.Y., Yoo N.J., Lee S.H.; RT "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular RT carcinomas."; RL Oncogene 24:1477-1480(2005). RN [30] RP VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT RP MET-391. RX PubMed=16533766; DOI=10.1158/1078-0432.ccr-05-2173; RA Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S., RA Bennett B.P., Su G.H.; RT "PIK3CA mutations in head and neck squamous cell carcinoma."; RL Clin. Cancer Res. 12:1441-1446(2006). RN [31] RP VARIANT CANCER ARG-1047. RX PubMed=16114017; DOI=10.1002/ijc.21444; RA Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.; RT "PIK3CA mutations in nasopharyngeal carcinoma."; RL Int. J. Cancer 118:1065-1067(2006). RN [32] RP VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047. RX PubMed=16353168; DOI=10.1002/path.1908; RA Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D., Fresu G., RA Salvatore S., Cuccurullo F., Mezzetti A., Campani D., Marchetti A.; RT "PIK3CA mutation and histological type in breast carcinoma: high frequency RT of mutations in lobular carcinoma."; RL J. Pathol. 208:350-355(2006). RN [33] RP CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=16432179; DOI=10.1073/pnas.0510857103; RA Bader A.G., Kang S., Vogt P.K.; RT "Cancer-specific mutations in PIK3CA are oncogenic in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006). RN [34] RP VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047. RX PubMed=17673550; DOI=10.1073/pnas.0705218104; RA Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E., RA Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R., RA Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A., Real F.X.; RT "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic RT keratoses with a characteristic mutation pattern."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007). RN [35] RP VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047. RX PubMed=22658544; DOI=10.1016/j.ajhg.2012.05.006; RA Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J., RA Spencer S.A., Mulliken J.B., Bowen M.E., Yamamoto G.L., Kozakewich H.P., RA Warman M.L.; RT "Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome."; RL Am. J. Hum. Genet. 90:1108-1115(2012). RN [36] RP VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; RP LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 RP AND SER-1049. RX PubMed=22729224; DOI=10.1038/ng.2331; RA Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., RA Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., RA Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., RA Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., RA Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., RA Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., RA Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E., RA O'Driscoll M., Shendure J., Graham J.M. Jr., Boycott K.M., Dobyns W.B.; RT "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA RT cause a spectrum of related megalencephaly syndromes."; RL Nat. Genet. 44:934-940(2012). RN [37] RP VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). RN [38] RP VARIANT MCAP ASN-112, CHARACTERIZATION OF VARIANT MCAP ASN-112, FUNCTION, RP AND SUBUNIT. RX PubMed=26593112; DOI=10.1002/humu.22933; RA Donato N.D., Rump A., Mirzaa G.M., Alcantara D., Oliver A., Schrock E., RA Dobyns W.B., O'Driscoll M.; RT "Identification and characterisation of a novel constitutional PIK3CA RT mutation in a child lacking the typical segmental overgrowth of 'PIK3CA- RT related overgrowth spectrum' (PROS)."; RL Hum. Mutat. 37:242-245(2016). CC -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates CC phosphatidylinositol (PI) and its phosphorylated derivatives at CC position 3 of the inositol ring to produce 3-phosphoinositides CC (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and CC PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate CC phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, CC PubMed:28676499). PIP3 plays a key role by recruiting PH domain- CC containing proteins to the membrane, including AKT1 and PDPK1, CC activating signaling cascades involved in cell growth, survival, CC proliferation, motility and morphology. Participates in cellular CC signaling in response to various growth factors. Involved in the CC activation of AKT1 upon stimulation by receptor tyrosine kinases CC ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in CC signaling via insulin-receptor substrate (IRS) proteins. Essential in CC endothelial cell migration during vascular development through VEGFA CC signaling, possibly by regulating RhoA activity. Required for lymphatic CC vasculature development, possibly by binding to RAS and by activation CC by EGF and FGF2, but not by PDGF. Regulates invadopodia formation CC through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in CC embryonic stem cells through a AKT1 pathway. Participates in CC vasculogenesis in embryonic stem cells through PDK1 and protein kinase CC C pathway. In addition to its lipid kinase activity, it displays a CC serine-protein kinase activity that results in the autophosphorylation CC of the p85alpha regulatory subunit as well as phosphorylation of other CC proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly CC others (PubMed:23936502, PubMed:28676499). Plays a role in the positive CC regulation of phagocytosis and pinocytosis (By similarity). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:15135396, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:23936502, CC ECO:0000269|PubMed:26593112, ECO:0000269|PubMed:28676499}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153; CC Evidence={ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293; CC Evidence={ECO:0000305|PubMed:15135396, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a CC 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP + CC H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216; CC EC=2.7.1.137; Evidence={ECO:0000269|PubMed:23936502}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710; CC Evidence={ECO:0000305|PubMed:23936502}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000305|PubMed:23936502, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:55632, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55633; CC Evidence={ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero- CC 3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2- CC (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo- CC inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137, CC ChEBI:CHEBI:83243, ChEBI:CHEBI:456216; CC Evidence={ECO:0000305|PubMed:15135396}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397; CC Evidence={ECO:0000305|PubMed:15135396}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=1.77 uM for PIP2 (1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate)) {ECO:0000269|PubMed:28676499}; CC KM=2.00 uM for ATP {ECO:0000269|PubMed:28676499}; CC Vmax=1.70 pmol/min/ng enzyme for the phosphorylation of PIP2 (1,2- CC dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)) CC {ECO:0000269|PubMed:28676499}; CC -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate CC biosynthesis. {ECO:0000305|PubMed:15135396, CC ECO:0000305|PubMed:28676499}. CC -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory CC subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112). Interacts with CC IRS1 in nuclear extracts (By similarity). Interacts with RUFY3 (By CC similarity). Interacts with RASD2 (By similarity). Interacts with CC APPL1. Interacts with HRAS and KRAS (By similarity). Interaction with CC HRAS/KRAS is required for PI3K pathway signaling and cell proliferation CC stimulated by EGF and FGF2 (By similarity). Interacts with FAM83B; CC activates the PI3K/AKT signaling cascade (PubMed:23676467). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:23676467, CC ECO:0000269|PubMed:26593112}. CC -!- INTERACTION: CC P42336; P54253: ATXN1; NbExp=3; IntAct=EBI-2116585, EBI-930964; CC P42336; P54252: ATXN3; NbExp=3; IntAct=EBI-2116585, EBI-946046; CC P42336; P21860: ERBB3; NbExp=18; IntAct=EBI-2116585, EBI-720706; CC P42336; P01100: FOS; NbExp=3; IntAct=EBI-2116585, EBI-852851; CC P42336; P62993: GRB2; NbExp=6; IntAct=EBI-2116585, EBI-401755; CC P42336; P42858: HTT; NbExp=3; IntAct=EBI-2116585, EBI-466029; CC P42336; P35568: IRS1; NbExp=42; IntAct=EBI-2116585, EBI-517592; CC P42336; P27986: PIK3R1; NbExp=63; IntAct=EBI-2116585, EBI-79464; CC P42336; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-2116585, EBI-9090282; CC P42336; O00459: PIK3R2; NbExp=49; IntAct=EBI-2116585, EBI-346930; CC P42336; Q92569: PIK3R3; NbExp=48; IntAct=EBI-2116585, EBI-79893; CC P42336; O43791: SPOP; NbExp=4; IntAct=EBI-2116585, EBI-743549; CC -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the CC PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the CC recruitment to the plasma membrane. The inhibitory interactions with CC PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain CC with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type CC domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with CC the nSH2 (N-terminal SH2) region of PIK3R1. CC {ECO:0000269|PubMed:18079394, ECO:0000269|PubMed:19805105}. CC -!- DISEASE: Note=PIK3CA mutations are involved in various type of cancer. CC Most of the cancer-associated mutations are missense mutations and map CC to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated CC isoforms participate in cellular transformation and tumorigenesis CC induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS/KRAS. CC Interaction with HRAS/KRAS is required for Ras-driven tumor formation. CC Mutations increasing the lipid kinase activity are required for CC oncogenic signaling. The protein kinase activity may not be required CC for tumorigenesis. {ECO:0000269|PubMed:15016963, CC ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, CC ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, CC ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16114017, CC ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, CC ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, CC ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:19805105, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22658544, CC ECO:0000269|PubMed:22729224}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:16353168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15520168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC {ECO:0000269|PubMed:15608678}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:17673550}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Megalencephaly-capillary malformation-polymicrogyria syndrome CC (MCAP) [MIM:602501]: A syndrome characterized by a spectrum of CC anomalies including primary megalencephaly, prenatal overgrowth, brain CC and body asymmetry, cutaneous vascular malformations, digital anomalies CC consisting of syndactyly with or without postaxial polydactyly, CC connective tissue dysplasia involving the skin, subcutaneous tissue, CC and joints, and cortical brain malformations, most distinctively CC polymicrogyria. {ECO:0000269|PubMed:22729224, CC ECO:0000269|PubMed:26593112}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital lipomatous overgrowth, vascular malformations, and CC epidermal nevi (CLOVE) [MIM:612918]: A sporadically occurring, non- CC hereditary disorder characterized by asymmetric somatic hypertrophy and CC anomalies in multiple organs. It is defined by four main clinical CC findings: congenital lipomatous overgrowth, vascular malformations, CC epidermal nevi, and skeletal/spinal abnormalities. The presence of CC truncal overgrowth and characteristic patterned macrodactyly at birth CC differentiates CLOVE from other syndromic forms of overgrowth. CC {ECO:0000269|PubMed:22658544}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 5 (CWS5) [MIM:615108]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:23246288}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: CLAPO syndrome (CLAPO) [MIM:613089]: A syndrome characterized CC by capillary malformation of the lower lip, lymphatic malformation of CC the face and neck, asymmetry of face and limbs and partial or CC generalised overgrowth. {ECO:0000269|PubMed:29446767}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC The tissue distribution of the clinical manifestations in CLAPO seems CC to follow a pattern of somatic mosaicism. CC {ECO:0000269|PubMed:29446767}. CC -!- DISEASE: Macrodactyly (MADAC) [MIM:155500]: A congenital anomaly CC characterized by fibrofatty tissue enlargement and bony overgrowth CC affecting the digits or the entire hand or foot. CC {ECO:0000269|PubMed:23100325}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. The tissue CC distribution of the clinical manifestations in MADAC seems to follow a CC pattern of somatic mosaicism. {ECO:0000269|PubMed:23100325}. CC -!- DISEASE: Cerebral cavernous malformations 4 (CCM4) [MIM:619538]: A form CC of cerebral cavernous malformations, a congenital vascular anomaly of CC the central nervous system that can result in hemorrhagic stroke, CC seizures, recurrent headaches, and focal neurologic deficits. The CC lesions are characterized by grossly enlarged blood vessels consisting CC of a single layer of endothelium and without any intervening neural CC tissue, ranging in diameter from a few millimeters to several CC centimeters. CCM4 cases occur sporadically. CC {ECO:0000269|PubMed:34496175}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hemifacial myohyperplasia (HFMH) [MIM:606773]: A rare disease CC characterized by facial asymmetry due to unilateral muscular CC hypertrophy mimicking spasm and orofacial dystonia. CC {ECO:0000269|PubMed:37712948}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an oncogene CC derived from PIK3CA. {ECO:0000305|PubMed:18418043}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE- CC ProRule:PRU00877, ECO:0000255|PROSITE-ProRule:PRU00879, CC ECO:0000255|PROSITE-ProRule:PRU00880}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/415/PIK3CA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z29090; CAA82333.1; -; mRNA. DR EMBL; U79143; AAB39753.1; -; mRNA. DR EMBL; BC113601; AAI13602.1; -; mRNA. DR EMBL; BC113603; AAI13604.1; -; mRNA. DR CCDS; CCDS43171.1; -. DR PIR; I38110; I38110. DR RefSeq; NP_006209.2; NM_006218.4. DR RefSeq; XP_006713721.1; XM_006713658.5. DR RefSeq; XP_054202817.1; XM_054346842.1. DR RefSeq; XP_054202818.1; XM_054346843.1. DR RefSeq; XP_054202819.1; XM_054346844.1. DR RefSeq; XP_054202820.1; XM_054346845.1. DR RefSeq; XP_054202821.1; XM_054346846.1. DR RefSeq; XP_054202822.1; XM_054346847.1. DR RefSeq; XP_054202823.1; XM_054346848.1. DR PDB; 2ENQ; NMR; -; A=331-481. DR PDB; 2RD0; X-ray; 3.05 A; A=1-1068. DR PDB; 3HHM; X-ray; 2.80 A; A=1-1068. DR PDB; 3HIZ; X-ray; 3.30 A; A=1-1068. DR PDB; 3ZIM; X-ray; 2.85 A; A=107-1046. DR PDB; 4JPS; X-ray; 2.20 A; A=1-1068. DR PDB; 4L1B; X-ray; 2.59 A; A=1-1068. DR PDB; 4L23; X-ray; 2.50 A; A=1-1068. DR PDB; 4L2Y; X-ray; 2.80 A; A=1-1068. DR PDB; 4OVU; X-ray; 2.96 A; A=1-1068. DR PDB; 4OVV; X-ray; 3.50 A; A=1-1068. DR PDB; 4TUU; X-ray; 2.64 A; A=105-1048. DR PDB; 4TV3; X-ray; 2.85 A; A=105-1048. DR PDB; 4WAF; X-ray; 2.39 A; A=2-1068. DR PDB; 4YKN; X-ray; 2.90 A; A=2-1068. DR PDB; 4ZOP; X-ray; 2.62 A; A=1-1068. DR PDB; 5DXH; X-ray; 3.00 A; A/D=2-1068. DR PDB; 5DXT; X-ray; 2.25 A; A=107-1068. DR PDB; 5FI4; X-ray; 2.50 A; A=1-1068. DR PDB; 5ITD; X-ray; 3.02 A; A=1-1068. DR PDB; 5SW8; X-ray; 3.30 A; A=1-1068. DR PDB; 5SWG; X-ray; 3.11 A; A=1-1068. DR PDB; 5SWO; X-ray; 3.50 A; A=1-1068. DR PDB; 5SWP; X-ray; 3.41 A; A=1-1068. DR PDB; 5SWR; X-ray; 3.31 A; A=1-1068. DR PDB; 5SWT; X-ray; 3.49 A; A=1-1068. DR PDB; 5SX8; X-ray; 3.47 A; A=1-1068. DR PDB; 5SX9; X-ray; 3.52 A; A=1-1068. DR PDB; 5SXA; X-ray; 3.35 A; A=1-1068. DR PDB; 5SXB; X-ray; 3.30 A; A=1-1068. DR PDB; 5SXC; X-ray; 3.55 A; A=1-1068. DR PDB; 5SXD; X-ray; 3.50 A; A=1-1068. DR PDB; 5SXE; X-ray; 3.51 A; A=1-1068. DR PDB; 5SXF; X-ray; 3.46 A; A=1-1068. DR PDB; 5SXI; X-ray; 3.40 A; A=1-1068. DR PDB; 5SXJ; X-ray; 3.42 A; A=1-1068. DR PDB; 5SXK; X-ray; 3.55 A; A=1-1068. DR PDB; 5UBR; X-ray; 2.40 A; A=107-1050. DR PDB; 5UK8; X-ray; 2.50 A; A=1-1068. DR PDB; 5UKJ; X-ray; 2.80 A; A=1-1068. DR PDB; 5UL1; X-ray; 3.00 A; A=1-1068. DR PDB; 5XGH; X-ray; 2.97 A; A=8-1055. DR PDB; 5XGI; X-ray; 2.56 A; A=8-1059. DR PDB; 5XGJ; X-ray; 2.97 A; A=8-1055. DR PDB; 6GVF; X-ray; 2.50 A; A=107-1051. DR PDB; 6GVG; X-ray; 3.00 A; A=107-1068. DR PDB; 6GVH; X-ray; 2.74 A; A=107-1068. DR PDB; 6GVI; X-ray; 2.90 A; A=107-1068. DR PDB; 6NCT; X-ray; 3.35 A; A=1-1068. DR PDB; 6OAC; X-ray; 3.15 A; A=105-1048. DR PDB; 6PYS; X-ray; 2.19 A; A=107-1051. DR PDB; 6VO7; X-ray; 2.31 A; A=157-300. DR PDB; 7JIU; X-ray; 2.12 A; A=107-1052. DR PDB; 7K6M; X-ray; 2.41 A; A=105-1048. DR PDB; 7K6N; X-ray; 2.77 A; A=105-1048. DR PDB; 7K6O; X-ray; 2.74 A; A=105-1048. DR PDB; 7K71; X-ray; 2.90 A; A=105-1048. DR PDB; 7L1B; X-ray; 2.04 A; C=1046-1054. DR PDB; 7L1C; X-ray; 1.96 A; C=1046-1054. DR PDB; 7L1D; X-ray; 3.11 A; C=1046-1054. DR PDB; 7MLK; X-ray; 2.91 A; A=105-1048. DR PDB; 7MYN; EM; 2.79 A; A=1-1068. DR PDB; 7MYO; EM; 2.92 A; A=1-1068. DR PDB; 7PG5; X-ray; 2.20 A; A=1-1068. DR PDB; 7PG6; X-ray; 2.50 A; A=1-1068. DR PDB; 7R9V; X-ray; 2.69 A; A=105-1048. DR PDB; 7R9Y; X-ray; 2.85 A; A=105-1048. DR PDB; 7RRG; X-ray; 2.12 A; C=1046-1054. DR PDB; 7TZ7; X-ray; 2.41 A; A=1-1068. DR PDB; 8AM0; X-ray; 2.82 A; A=1-1068. DR PDB; 8BFU; X-ray; 2.41 A; A=105-1048. DR PDB; 8DCP; EM; 2.41 A; A=1-1068. DR PDB; 8DCX; EM; 2.80 A; A=1-1068. DR PDB; 8DD4; EM; 3.10 A; A=1-1068. DR PDB; 8DD8; EM; 3.40 A; A=1-1068. DR PDB; 8EXL; X-ray; 1.99 A; A=7-1052. DR PDB; 8EXO; X-ray; 2.46 A; A=7-1052. DR PDB; 8EXU; X-ray; 2.68 A; A=7-1052. DR PDB; 8EXV; X-ray; 2.48 A; A=7-1052. DR PDB; 8GUA; EM; 2.77 A; A=1-1068. DR PDB; 8GUB; EM; 2.73 A; A=1-1068. DR PDB; 8GUD; EM; 2.62 A; A=1-1068. DR PDB; 8ILR; EM; 3.05 A; A=1-1068. DR PDB; 8ILS; EM; 3.10 A; A=1-1068. DR PDB; 8ILV; EM; 3.19 A; A=1-1068. DR PDB; 8OW2; X-ray; 2.57 A; A=105-1048. DR PDB; 8SBC; X-ray; 2.30 A; A=1-1068. DR PDB; 8SBJ; X-ray; 3.10 A; A=1-1068. DR PDB; 8TDU; X-ray; 3.11 A; A/C=1-1068. DR PDB; 8TGD; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8TS7; X-ray; 2.71 A; A=2-1053. DR PDB; 8TS8; X-ray; 2.72 A; A=2-1053. DR PDB; 8TS9; X-ray; 2.83 A; A=2-1050. DR PDB; 8TSA; X-ray; 2.51 A; A=2-1050. DR PDB; 8TSB; X-ray; 3.53 A; A=2-1053. DR PDB; 8TSC; X-ray; 3.62 A; A=2-1050. DR PDB; 8TSD; X-ray; 2.70 A; A=2-1053. DR PDB; 8TU6; EM; 3.12 A; A=2-1068. DR PDB; 8TWY; X-ray; 2.67 A; A=105-1048. DR PDB; 8V8H; X-ray; 3.58 A; A/C=1-1068. DR PDB; 8V8I; X-ray; 3.20 A; A/C=1-1068. DR PDB; 8V8J; X-ray; 3.35 A; A/C=1-1068. DR PDB; 8V8U; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8V8V; X-ray; 2.61 A; A/C=1-1068. DR PDB; 8VCL; X-ray; 2.40 A; C=1046-1054. DR PDB; 8W9A; EM; 2.70 A; A=1-1068. DR PDB; 8W9B; EM; 3.00 A; A=1-1068. DR PDB; 9ASF; X-ray; 1.77 A; C=1046-1054. DR PDB; 9ASG; X-ray; 2.03 A; C=1046-1054. DR PDB; 9B4S; X-ray; 3.10 A; A=105-1068. DR PDB; 9B4T; X-ray; 2.75 A; A=105-1068. DR PDB; 9B4U; X-ray; 2.21 A; A/B=157-300. DR PDB; 9C15; X-ray; 2.81 A; A=105-1068. DR PDB; 9CMK; X-ray; 1.75 A; A/B=160-300. DR PDB; 9CML; X-ray; 2.01 A; A/B=160-300. DR PDB; 9CMV; X-ray; 3.01 A; A=105-1068. DR PDB; 9E8M; X-ray; 2.83 A; A/B=157-300. DR PDBsum; 2ENQ; -. DR PDBsum; 2RD0; -. DR PDBsum; 3HHM; -. DR PDBsum; 3HIZ; -. DR PDBsum; 3ZIM; -. DR PDBsum; 4JPS; -. DR PDBsum; 4L1B; -. DR PDBsum; 4L23; -. DR PDBsum; 4L2Y; -. DR PDBsum; 4OVU; -. DR PDBsum; 4OVV; -. DR PDBsum; 4TUU; -. DR PDBsum; 4TV3; -. DR PDBsum; 4WAF; -. DR PDBsum; 4YKN; -. DR PDBsum; 4ZOP; -. DR PDBsum; 5DXH; -. DR PDBsum; 5DXT; -. DR PDBsum; 5FI4; -. DR PDBsum; 5ITD; -. DR PDBsum; 5SW8; -. DR PDBsum; 5SWG; -. DR PDBsum; 5SWO; -. DR PDBsum; 5SWP; -. DR PDBsum; 5SWR; -. DR PDBsum; 5SWT; -. DR PDBsum; 5SX8; -. DR PDBsum; 5SX9; -. DR PDBsum; 5SXA; -. DR PDBsum; 5SXB; -. DR PDBsum; 5SXC; -. DR PDBsum; 5SXD; -. DR PDBsum; 5SXE; -. DR PDBsum; 5SXF; -. DR PDBsum; 5SXI; -. DR PDBsum; 5SXJ; -. DR PDBsum; 5SXK; -. DR PDBsum; 5UBR; -. DR PDBsum; 5UK8; -. DR PDBsum; 5UKJ; -. DR PDBsum; 5UL1; -. DR PDBsum; 5XGH; -. DR PDBsum; 5XGI; -. DR PDBsum; 5XGJ; -. DR PDBsum; 6GVF; -. DR PDBsum; 6GVG; -. DR PDBsum; 6GVH; -. DR PDBsum; 6GVI; -. DR PDBsum; 6NCT; -. DR PDBsum; 6OAC; -. DR PDBsum; 6PYS; -. DR PDBsum; 6VO7; -. DR PDBsum; 7JIU; -. DR PDBsum; 7K6M; -. DR PDBsum; 7K6N; -. DR PDBsum; 7K6O; -. DR PDBsum; 7K71; -. DR PDBsum; 7L1B; -. DR PDBsum; 7L1C; -. DR PDBsum; 7L1D; -. DR PDBsum; 7MLK; -. DR PDBsum; 7MYN; -. DR PDBsum; 7MYO; -. DR PDBsum; 7PG5; -. DR PDBsum; 7PG6; -. DR PDBsum; 7R9V; -. DR PDBsum; 7R9Y; -. DR PDBsum; 7RRG; -. DR PDBsum; 7TZ7; -. DR PDBsum; 8AM0; -. DR PDBsum; 8BFU; -. DR PDBsum; 8DCP; -. DR PDBsum; 8DCX; -. DR PDBsum; 8DD4; -. DR PDBsum; 8DD8; -. DR PDBsum; 8EXL; -. DR PDBsum; 8EXO; -. DR PDBsum; 8EXU; -. DR PDBsum; 8EXV; -. DR PDBsum; 8GUA; -. DR PDBsum; 8GUB; -. DR PDBsum; 8GUD; -. DR PDBsum; 8ILR; -. DR PDBsum; 8ILS; -. DR PDBsum; 8ILV; -. DR PDBsum; 8OW2; -. DR PDBsum; 8SBC; -. DR PDBsum; 8SBJ; -. DR PDBsum; 8TDU; -. DR PDBsum; 8TGD; -. DR PDBsum; 8TS7; -. DR PDBsum; 8TS8; -. DR PDBsum; 8TS9; -. DR PDBsum; 8TSA; -. DR PDBsum; 8TSB; -. DR PDBsum; 8TSC; -. DR PDBsum; 8TSD; -. DR PDBsum; 8TU6; -. DR PDBsum; 8TWY; -. DR PDBsum; 8V8H; -. DR PDBsum; 8V8I; -. DR PDBsum; 8V8J; -. DR PDBsum; 8V8U; -. DR PDBsum; 8V8V; -. DR PDBsum; 8VCL; -. DR PDBsum; 8W9A; -. DR PDBsum; 8W9B; -. DR PDBsum; 9ASF; -. DR PDBsum; 9ASG; -. DR PDBsum; 9B4S; -. DR PDBsum; 9B4T; -. DR PDBsum; 9B4U; -. DR PDBsum; 9C15; -. DR PDBsum; 9CMK; -. DR PDBsum; 9CML; -. DR PDBsum; 9CMV; -. DR PDBsum; 9E8M; -. DR AlphaFoldDB; P42336; -. DR EMDB; EMD-24081; -. DR EMDB; EMD-24082; -. DR EMDB; EMD-27327; -. DR EMDB; EMD-27330; -. DR EMDB; EMD-27334; -. DR EMDB; EMD-27336; -. DR EMDB; EMD-34271; -. DR EMDB; EMD-34272; -. DR EMDB; EMD-34273; -. DR EMDB; EMD-35543; -. DR EMDB; EMD-35545; -. DR EMDB; EMD-35547; -. DR EMDB; EMD-37362; -. DR EMDB; EMD-37363; -. DR EMDB; EMD-41617; -. DR SMR; P42336; -. DR BioGRID; 111308; 178. DR ComplexPortal; CPX-1917; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85beta. DR ComplexPortal; CPX-1918; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55gamma. DR ComplexPortal; CPX-2384; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85alpha. DR ComplexPortal; CPX-5970; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55alpha. DR ComplexPortal; CPX-5971; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p50alpha. DR CORUM; P42336; -. DR DIP; DIP-42728N; -. DR FunCoup; P42336; 3134. DR IntAct; P42336; 216. DR MINT; P42336; -. DR STRING; 9606.ENSP00000263967; -. DR BindingDB; P42336; -. DR ChEMBL; CHEMBL4005; -. DR DrugBank; DB12015; Alpelisib. DR DrugBank; DB00171; ATP. DR DrugBank; DB11666; Buparlisib. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB13051; CH-5132799. DR DrugBank; DB12483; Copanlisib. DR DrugBank; DB15275; Inavolisib. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB11772; Pilaralisib. DR DrugBank; DB14935; Serabelisib. DR DrugBank; DB12108; Taselisib. DR DrugBank; DB08059; Wortmannin. DR DrugBank; DB05241; XL765. DR DrugCentral; P42336; -. DR GuidetoPHARMACOLOGY; 2153; -. DR iPTMnet; P42336; -. DR MetOSite; P42336; -. DR PhosphoSitePlus; P42336; -. DR BioMuta; PIK3CA; -. DR DMDM; 126302584; -. DR CPTAC; CPTAC-1631; -. DR CPTAC; CPTAC-3127; -. DR CPTAC; CPTAC-3128; -. DR CPTAC; CPTAC-3129; -. DR jPOST; P42336; -. DR MassIVE; P42336; -. DR PaxDb; 9606-ENSP00000263967; -. DR PeptideAtlas; P42336; -. DR ProteomicsDB; 55509; -. DR Pumba; P42336; -. DR Antibodypedia; 1374; 746 antibodies from 44 providers. DR CPTC; P42336; 1 antibody. DR DNASU; 5290; -. DR Ensembl; ENST00000263967.4; ENSP00000263967.3; ENSG00000121879.7. DR GeneID; 5290; -. DR KEGG; hsa:5290; -. DR MANE-Select; ENST00000263967.4; ENSP00000263967.3; NM_006218.4; NP_006209.2. DR UCSC; uc003fjk.4; human. DR AGR; HGNC:8975; -. DR CIViC; 5290; 319 evidence items across 211 molecular profiles. DR ClinPGx; PA33308; -. DR CTD; 5290; -. DR DisGeNET; 5290; -. DR GeneCards; PIK3CA; -. DR GeneReviews; PIK3CA; -. DR HGNC; HGNC:8975; PIK3CA. DR HPA; ENSG00000121879; Low tissue specificity. DR MalaCards; PIK3CA; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 114550; phenotype. DR MIM; 155500; phenotype. DR MIM; 167000; phenotype. DR MIM; 171834; gene. DR MIM; 182000; phenotype. DR MIM; 602501; phenotype. DR MIM; 606773; phenotype. DR MIM; 612918; phenotype. DR MIM; 613089; phenotype. DR MIM; 615108; phenotype. DR MIM; 619538; phenotype. DR OpenTargets; ENSG00000121879; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 90308; Capillary-lymphatic-venous malformation with segmental distribution. DR Orphanet; 168984; CLAPO syndrome. DR Orphanet; 140944; CLOVES syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 221061; Familial cerebral cavernous malformation. DR Orphanet; 276280; Hemihyperplasia-multiple lipomatosis syndrome. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 295239; Macrodactyly of fingers, unilateral. DR Orphanet; 295243; Macrodactyly of toes, unilateral. DR Orphanet; 60040; Megalencephaly-capillary malformation-polymicrogyria syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 314662; Segmental progressive overgrowth syndrome with fibroadipose hyperplasia. DR VEuPathDB; HostDB:ENSG00000121879; -. DR eggNOG; KOG0904; Eukaryota. DR GeneTree; ENSGT00940000155531; -. DR HOGENOM; CLU_002191_1_1_1; -. DR InParanoid; P42336; -. DR OMA; RWSEWLN; -. DR OrthoDB; 67688at2759; -. DR PAN-GO; P42336; 9 GO annotations based on evolutionary models. DR PhylomeDB; P42336; -. DR BioCyc; MetaCyc:HS04527-MONOMER; -. DR BRENDA; 2.7.1.137; 2681. DR BRENDA; 2.7.1.153; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P42336; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-112399; IRS-mediated signalling. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-198203; PI3K/AKT activation. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization. DR Reactome; R-HSA-373753; Nephrin family interactions. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-416476; G alpha (q) signalling events. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654689; PI-3K cascade:FGFR1. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K). DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-912631; Regulation of signaling by CBL. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9842640; Signaling by LTK in cancer. DR Reactome; R-HSA-9842663; Signaling by LTK. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9927354; Co-stimulation by ICOS. DR SABIO-RK; P42336; -. DR SignaLink; P42336; -. DR SIGNOR; P42336; -. DR UniPathway; UPA00220; -. DR Agora; ENSG00000121879; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5290; 275 hits in 1174 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PIK3CA; human. DR EvolutionaryTrace; P42336; -. DR GeneWiki; P110%CE%B1; -. DR GenomeRNAi; 5290; -. DR Pharos; P42336; Tclin. DR PRO; PR:P42336; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P42336; protein. DR Bgee; ENSG00000121879; Expressed in calcaneal tendon and 201 other cell types or tissues. DR ExpressionAtlas; P42336; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0014704; C:intercalated disc; ISS:BHF-UCL. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:BHF-UCL. DR GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL. DR GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IDA:UniProtKB. DR GO; GO:0005944; C:phosphatidylinositol 3-kinase complex, class IB; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB. DR GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IDA:UniProt. DR GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl. DR GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0141068; P:autosome genomic imprinting; IEA:Ensembl. DR GO; GO:0086003; P:cardiac muscle cell contraction; ISS:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071464; P:cellular response to hydrostatic pressure; ISS:BHF-UCL. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0030835; P:negative regulation of actin filament depolymerization; ISS:BHF-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; ISS:BHF-UCL. DR GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central. DR GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central. DR GO; GO:0030168; P:platelet activation; TAS:UniProtKB. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISS:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:1905477; P:positive regulation of protein localization to membrane; IDA:UniProt. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032008; P:positive regulation of TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0110053; P:regulation of actin filament organization; ISS:BHF-UCL. DR GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl. DR GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl. DR GO; GO:0055119; P:relaxation of cardiac muscle; ISS:BHF-UCL. DR GO; GO:0014823; P:response to activity; IEA:Ensembl. DR GO; GO:1903544; P:response to butyrate; IEA:Ensembl. DR GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl. DR GO; GO:0043201; P:response to L-leucine; IEA:Ensembl. DR GO; GO:0014870; P:response to muscle inactivity; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; ISS:BHF-UCL. DR GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome. DR GO; GO:0038203; P:TORC2 signaling; IMP:MGI. DR GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IGI:BHF-UCL. DR GO; GO:0001944; P:vasculature development; TAS:UniProtKB. DR CDD; cd08398; C2_PI3K_class_I_alpha; 1. DR CDD; cd00872; PI3Ka_I; 1. DR CDD; cd05175; PI3Kc_IA_alpha; 1. DR FunFam; 1.10.1070.11:FF:000006; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 1.25.40.70:FF:000001; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 2.60.40.150:FF:000041; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000055; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000074; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000007; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR037704; PI3-kinase_alpha_cat. DR InterPro; IPR015433; PI3/4_kinase. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR002420; PI3K-type_C2_dom. DR InterPro; IPR003113; PI3K_ABD. DR InterPro; IPR001263; PI3K_accessory_dom. DR InterPro; IPR042236; PI3K_accessory_sf. DR InterPro; IPR000341; PI3K_Ras-bd_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10048:SF107; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; 1. DR PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF00792; PI3K_C2; 1. DR Pfam; PF02192; PI3K_p85B; 1. DR Pfam; PF00794; PI3K_rbd; 1. DR Pfam; PF00613; PI3Ka; 1. DR SMART; SM00142; PI3K_C2; 1. DR SMART; SM00143; PI3K_p85B; 1. DR SMART; SM00144; PI3K_rbd; 1. DR SMART; SM00145; PI3Ka; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS51547; C2_PI3K; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. DR PROSITE; PS51544; PI3K_ABD; 1. DR PROSITE; PS51546; PI3K_RBD; 1. DR PROSITE; PS51545; PIK_HELICAL; 1. PE 1: Evidence at protein level; KW 3D-structure; Angiogenesis; ATP-binding; Disease variant; Kinase; KW Lipid metabolism; Nucleotide-binding; Phagocytosis; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1068 FT /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase FT catalytic subunit alpha isoform" FT /id="PRO_0000088785" FT DOMAIN 16..105 FT /note="PI3K-ABD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00877" FT DOMAIN 187..289 FT /note="PI3K-RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00879" FT DOMAIN 330..487 FT /note="C2 PI3K-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00880" FT DOMAIN 517..694 FT /note="PIK helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00878" FT DOMAIN 765..1051 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 771..777 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 912..920 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 931..957 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 776 FT /note="Implicated in the recognition of ATP as well as FT PIP2. Also crucial for autophosphorylation of the p85alpha FT subunit" FT /evidence="ECO:0000305|PubMed:23936502" FT VARIANT 38 FT /note="R -> H (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction between the PI3K-ABD domain and FT the N-terminal lobe of PI3K/PI4K kinase domain possibly FT affecting the conformation of the kinase domain; FT dbSNP:rs772110575)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026166" FT VARIANT 43 FT /note="I -> V (in dbSNP:rs1051399)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042942" FT VARIANT 81 FT /note="E -> K (in MCAP; dbSNP:rs1057519929)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069251" FT VARIANT 83 FT /note="F -> S (in CLAPO; uncertain significance; somatic FT mutation; dbSNP:rs1560137208)" FT /evidence="ECO:0000269|PubMed:29446767" FT /id="VAR_081475" FT VARIANT 88 FT /note="R -> Q (in MCAP; also found in a glioblastoma FT multiforme sample; dbSNP:rs121913287)" FT /evidence="ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026167" FT VARIANT 106 FT /note="G -> V (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT dbSNP:rs1057519930)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026168" FT VARIANT 112 FT /note="I -> N (in MCAP; increased phosphatidylinositol 3- FT kinase signaling; decreased interaction with p85 regulatory FT subunit; no effect on protein abundance; FT dbSNP:rs863225460)" FT /evidence="ECO:0000269|PubMed:26593112" FT /id="VAR_075634" FT VARIANT 115 FT /note="R -> P (in CLAPO and MADAC; uncertain significance; FT somatic mutation in CLAPO and MADAC patients; FT dbSNP:rs200018596)" FT /evidence="ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767" FT /id="VAR_081476" FT VARIANT 118 FT /note="G -> D (in CWS5; dbSNP:rs587777790)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069786" FT VARIANT 135 FT /note="E -> K (in CWS5; dbSNP:rs587777791)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069787" FT VARIANT 218 FT /note="E -> K (in CWS5; dbSNP:rs587777792)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069788" FT VARIANT 332 FT /note="S -> R (in dbSNP:rs1051407)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042943" FT VARIANT 343 FT /note="Y -> C (found in a cancer sample; uncertain FT significance; dbSNP:rs2108393253)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026169" FT VARIANT 356 FT /note="V -> I (in CWS5; dbSNP:rs587777793)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069789" FT VARIANT 364 FT /note="G -> R (in MCAP; dbSNP:rs1576935161)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069252" FT VARIANT 365 FT /note="E -> K (in MCAP; dbSNP:rs1064793732)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069253" FT VARIANT 378 FT /note="C -> Y (in MCAP; dbSNP:rs397514565)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069254" FT VARIANT 382 FT /note="R -> K (in CWS5; dbSNP:rs587777794)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069790" FT VARIANT 391 FT /note="I -> M (in dbSNP:rs2230461)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026170" FT VARIANT 420 FT /note="C -> R (in CLOVE, CRC and CLAPO; uncertain FT significance; somatic mutation in CLAPO patients; shows an FT increase in lipid kinase activity; may increase the FT affinity for lipid membranes; dbSNP:rs121913272)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:29446767" FT /id="VAR_026171" FT VARIANT 453 FT /note="E -> Q (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction of the C2 PI3K-type domain with FT the iSH2 region of the p85 regulatory subunit; FT dbSNP:rs1057519925)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026172" FT VARIANT 453 FT /note="Missing (in MCAP)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069255" FT VARIANT 542 FT /note="E -> K (in CLOVE, KERSEB, CRC, BC, CLAPO, MADAC, FT CCM4 and HFMH; somatic mutation; also found in glioblastoma FT multiforme and endometrial carcinoma; somatic mutation; FT shows an increase in lipid kinase activity; oncogenic in FT vivo; occurs in the interface between the PI3K helical FT domain and the nSH2 (N-terminal SH2) region of the p85 FT regulatory subunit and may reduce the inhibitory effect of FT p85; requires interaction with RAS to induce cellular FT transformation; increased AKT and RPS6 phosphorylation in FT HFMH patient's cells; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, FT ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, FT ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:22658544, FT ECO:0000269|PubMed:23100325, ECO:0000269|PubMed:29446767, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026173" FT VARIANT 542 FT /note="E -> Q (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026174" FT VARIANT 542 FT /note="E -> V (in BC; uncertain significance; FT dbSNP:rs1057519927)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026175" FT VARIANT 545 FT /note="E -> A (in CWS5 and HCC; also found in a FT glioblastoma multiforme sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15608678, FT ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:23246288" FT /id="VAR_026176" FT VARIANT 545 FT /note="E -> G (in KERSEB; also found in an endometrial FT carcinoma sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:17673550" FT /id="VAR_026177" FT VARIANT 545 FT /note="E -> K (in MCAP, KERSEB, CRC, BC and HFMH; somatic FT mutation; shows an increase in lipid kinase activity; FT oncogenic in vivo; occurs in the interface between the PI3K FT helical domain and the nSH2 (N-terminal SH2) region of the FT p85 regulatory subunit and may reduce the inhibitory effect FT of p85; requires interaction with RAS to induce cellular FT transformation; enhances invadopodia-mediated extracellular FT matrix degradation and invasion in breast cancer cells; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cells; dbSNP:rs104886003)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15712344, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22729224, FT ECO:0000269|PubMed:37712948" FT /id="VAR_026178" FT VARIANT 546 FT /note="Q -> E (in BC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026179" FT VARIANT 546 FT /note="Q -> K (in OC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026180" FT VARIANT 546 FT /note="Q -> P (found in an anaplastic astrocytoma sample; FT uncertain significance; dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026181" FT VARIANT 546 FT /note="Q -> R (in BC; uncertain significance; FT dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026182" FT VARIANT 726 FT /note="E -> K (in MCAP; dbSNP:rs867262025)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069256" FT VARIANT 914 FT /note="G -> R (in MCAP; dbSNP:rs587776932)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069257" FT VARIANT 1007 FT /note="G -> R (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1448660730)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026183" FT VARIANT 1021 FT /note="Y -> C (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913288)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026184" FT VARIANT 1021 FT /note="Y -> H (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026185" FT VARIANT 1021 FT /note="Y -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026186" FT VARIANT 1023 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs2108429549)" FT /evidence="ECO:0000269|PubMed:15994075" FT /id="VAR_026187" FT VARIANT 1025 FT /note="T -> A (in MCAP; dbSNP:rs397517202)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069258" FT VARIANT 1025 FT /note="T -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs1553826166)" FT /evidence="ECO:0000269|PubMed:15924253" FT /id="VAR_026188" FT VARIANT 1035 FT /note="A -> V (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs1242945375)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026189" FT VARIANT 1043 FT /note="M -> I (in MCAP and CRC; also found in an FT endometrial carcinoma sample; shows an increase in lipid FT kinase activity; dbSNP:rs121913283)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:22729224" FT /id="VAR_026190" FT VARIANT 1047 FT /note="H -> L (in BC, CLAPO, MADAC and CCM4; somatic FT mutation; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767, ECO:0000269|PubMed:34496175" FT /id="VAR_026191" FT VARIANT 1047 FT /note="H -> R (in CLOVE, KERSEB, CRC, BC, OC, MADAC, CCM4 FT and HFMH; also found in an endometrial carcinoma sample; FT somatic mutation; shows an increase in lipid kinase FT activity; oncogenic in vivo; requires binding to p85 FT regulatory subunit to induce cellular transformation but FT not interaction with RAS; may mimic the conformatitonal FT change triggered by the interaction with RAS; enhances FT invadopodia-mediated extracellular matrix degradation and FT invasion in breast cancer cells; may alter the interaction FT of the PI3K/PI4K kinase domain with the cell membrane; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cell; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15016963, FT ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16114017, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:21708979, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026192" FT VARIANT 1047 FT /note="H -> Y (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913281)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026193" FT VARIANT 1049 FT /note="G -> S (in MCAP; dbSNP:rs121913277)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069259" FT VARIANT 1050 FT /note="G -> D (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429937)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026194" FT VARIANT 1052 FT /note="T -> K (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429956)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026195" FT VARIANT 1065 FT /note="H -> L (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1560150596)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026196" FT VARIANT 1065 FT /note="H -> Y (found in brain tumors; uncertain FT significance; dbSNP:rs2108430115)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026197" FT CONFLICT 170 FT /note="N -> H (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 286..287 FT /note="ML -> KM (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="V -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 723 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 751 FT /note="F -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 767 FT /note="E -> K (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT STRAND 5..10 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 18..25 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 27..29 FT /evidence="ECO:0007829|PDB:8TSA" FT STRAND 31..37 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 42..52 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 59..61 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 69..74 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4OVU" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 89..91 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 94..102 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5SXA" FT HELIX 108..121 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 126..129 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 134..142 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 144..154 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 155..159 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 160..166 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 179..182 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 183..185 FT /evidence="ECO:0007829|PDB:3HHM" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:8BFU" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 199..202 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 204..212 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:8V8V" FT HELIX 236..246 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 247..249 FT /evidence="ECO:0007829|PDB:7JIU" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8W9A" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8W9B" FT STRAND 263..265 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 271..279 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 284..289 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 290..294 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:5SXA" FT STRAND 323..326 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 332..343 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 348..350 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 353..362 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 365..368 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 378..380 FT /evidence="ECO:0007829|PDB:6PYS" FT STRAND 382..392 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 393..395 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 400..408 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 413..415 FT /evidence="ECO:0007829|PDB:8SBC" FT STRAND 420..430 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 434..436 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 439..444 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8GUA" FT STRAND 454..456 FT /evidence="ECO:0007829|PDB:6GVF" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:8V8V" FT STRAND 468..470 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 481..485 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 489..504 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 508..511 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:4TUU" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 525..536 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 539..541 FT /evidence="ECO:0007829|PDB:4TUU" FT HELIX 545..553 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 562..564 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 565..569 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:8W9A" FT HELIX 577..588 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 595..598 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 599..602 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 603..605 FT /evidence="ECO:0007829|PDB:8GUD" FT HELIX 609..622 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 625..630 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 632..638 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 639..641 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 661..672 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 673..676 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 681..694 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 724..726 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 728..739 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 742..747 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 749..753 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 756..761 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 766..768 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 773..776 FT /evidence="ECO:0007829|PDB:8DCP" FT STRAND 779..784 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 786..789 FT /evidence="ECO:0007829|PDB:7MYN" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 795..805 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 808..826 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 838..842 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 845..849 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 852..856 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 857..860 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 863..865 FT /evidence="ECO:0007829|PDB:7K6N" FT STRAND 866..868 FT /evidence="ECO:0007829|PDB:8TSA" FT HELIX 869..871 FT /evidence="ECO:0007829|PDB:7K6N" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 876..884 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7JIU" FT HELIX 890..911 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 920..924 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 925..927 FT /evidence="ECO:0007829|PDB:8GUD" FT STRAND 929..931 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 935..937 FT /evidence="ECO:0007829|PDB:8W9B" FT TURN 938..941 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 948..950 FT /evidence="ECO:0007829|PDB:7K6M" FT STRAND 951..954 FT /evidence="ECO:0007829|PDB:7K6M" FT HELIX 958..964 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 965..967 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 971..973 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 975..993 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 995..1003 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1004..1007 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1013..1015 FT /evidence="ECO:0007829|PDB:8EXV" FT HELIX 1016..1025 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1026..1029 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 1032..1047 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1048..1050 FT /evidence="ECO:0007829|PDB:5SW8" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:3HHM" FT STRAND 1056..1058 FT /evidence="ECO:0007829|PDB:4JPS" SQ SEQUENCE 1068 AA; 124284 MW; 041487231A9A1207 CRC64; MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN //